<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87434</article-id><article-id pub-id-type="doi">10.7554/eLife.87434</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.87434.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Styxl2 regulates de novo sarcomere assembly by binding to non-muscle myosin IIs and promoting their degradation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-309672"><name><surname>Chen</surname><given-names>Xianwei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5646-3245</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-309702"><name><surname>Li</surname><given-names>Yanfeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-106922"><name><surname>Xu</surname><given-names>Jin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6840-1359</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309703"><name><surname>Cui</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309704"><name><surname>Wu</surname><given-names>Qian</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309705"><name><surname>Yin</surname><given-names>Haidi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-309706"><name><surname>Li</surname><given-names>Yuying</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-345812"><name><surname>Gao</surname><given-names>Chuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5184"><name><surname>Jiang</surname><given-names>Liwen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-162787"><name><surname>Wang</surname><given-names>Huating</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5474-2905</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59387"><name><surname>Wen</surname><given-names>Zilong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210977"><name><surname>Yao</surname><given-names>Zhongping</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-201571"><name><surname>Wu</surname><given-names>Zhenguo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3049-8324</contrib-id><email>bczgwu@ust.hk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00q4vv597</institution-id><institution>Division of Life Science, Hong Kong University of Science &amp; Technology</institution></institution-wrap><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t33hh48</institution-id><institution>School of Life Sciences, Chinese University of Hong Kong</institution></institution-wrap><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0030zas98</institution-id><institution>Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University</institution></institution-wrap><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t33hh48</institution-id><institution>Department of Orthopaedics and Traumatology, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong</institution></institution-wrap><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mizushima</surname><given-names>Noboru</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0243gzr89</institution-id><institution>Max Planck Institute for Biology Tübingen</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>06</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP87434</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-03-12"><day>12</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-03-04"><day>04</day><month>03</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.22.513336"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-05-05"><day>05</day><month>05</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87434.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-23"><day>23</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87434.2"/></event></pub-history><permissions><copyright-statement>© 2023, Chen, Li et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Chen, Li et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87434-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-87434-figures-v1.pdf"/><abstract><p>Styxl2, a poorly characterized pseudophosphatase, was identified as a transcriptional target of the Jak1-Stat1 pathway during myoblast differentiation in culture. Styxl2 is specifically expressed in vertebrate striated muscles. By gene knockdown in zebrafish or genetic knockout in mice, we found that Styxl2 plays an essential role in maintaining sarcomere integrity in developing muscles. To further reveal the functions of Styxl2 in adult muscles, we generated two inducible knockout mouse models: one with <italic>Styxl2</italic> being deleted in mature myofibers to assess its role in sarcomere maintenance, and the other in adult muscle satellite cells (MuSCs) to assess its role in de novo sarcomere assembly. We find that Styxl2 is not required for sarcomere maintenance but functions in de novo sarcomere assembly during injury-induced muscle regeneration. Mechanistically, Styxl2 interacts with non-muscle myosin IIs, enhances their ubiquitination, and targets them for autophagy-dependent degradation. Without Styxl2, the degradation of non-muscle myosin IIs is delayed, which leads to defective sarcomere assembly and force generation. Thus, Styxl2 promotes de novo sarcomere assembly by interacting with non-muscle myosin IIs and facilitating their autophagic degradation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Styxl2</kwd><kwd>pseudophosphatase</kwd><kwd>sarcomere assembly</kwd><kwd>non-muscle myosin II</kwd><kwd>autophagy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002920</institution-id><institution>Research Grants Council, University Grants Committee</institution></institution-wrap></funding-source><award-id>C6018-19G</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhenguo</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002920</institution-id><institution>Research Grants Council, University Grants Committee</institution></institution-wrap></funding-source><award-id>AoE/M-604/16</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhenguo</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002920</institution-id><institution>Research Grants Council, University Grants Committee</institution></institution-wrap></funding-source><award-id>T13-602/21-N</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhenguo</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002920</institution-id><institution>Research Grants Council, University Grants Committee</institution></institution-wrap></funding-source><award-id>T13-605/18-W</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhenguo</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100021177</institution-id><institution>Shenzhen Bay Laboratory</institution></institution-wrap></funding-source><award-id>S201101002</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhenguo</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003452</institution-id><institution>Innovation and Technology Commission</institution></institution-wrap></funding-source><award-id>HKCeND</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhenguo</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003452</institution-id><institution>Innovation and Technology Commission</institution></institution-wrap></funding-source><award-id>the State Key Laboratory of Molecular Neuroscience at HKUST</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Zhenguo</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Styxl2, a sarcomeric muscle-specific pseudophosphatase in vertebrates, functions in sarcomere assembly by promoting protein degradation of non-muscle myosin IIs.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Striated muscles, including skeletal and cardiac muscles of vertebrates and some muscles of invertebrates, are unique in that they contain highly-organized, multi-protein contractile structures called myofibrils in the cytosol of myofibers or cardiomyocytes (<xref ref-type="bibr" rid="bib15">Clark et al., 2002</xref>; <xref ref-type="bibr" rid="bib54">Mukund and Subramaniam, 2020</xref>; <xref ref-type="bibr" rid="bib79">Sparrow and Schöck, 2009</xref>). Sarcomeres are the smallest repeating structural units of myofibrils responsible for muscle contraction (<xref ref-type="bibr" rid="bib4">Avellaneda et al., 2021</xref>; <xref ref-type="bibr" rid="bib80">Squire, 2005</xref>). A sarcomere is flanked by Z-discs (or Z lines) with multiple actin filaments (or thin filaments) anchored to the Z-discs in parallel and the interdigitating bipolar myosin bundles (or thick filaments) anchored to the M-line in the middle of the sarcomere (<xref ref-type="bibr" rid="bib80">Squire, 2005</xref>). As a key component of the Z-disc, an anti-parallel α-actinin dimer directly binds to two actin filaments in opposite directions (<xref ref-type="bibr" rid="bib80">Squire, 2005</xref>). A sarcomere can be further divided into the lighter I (isotropic)-band and the darker A (anisotropic)-band based on their microscopic appearances with the I-band containing actin filaments only and the A-band containing both the myosin bundles and partially overlapping actin filaments (<xref ref-type="bibr" rid="bib18">Craig and Padrón, 2004</xref>; <xref ref-type="bibr" rid="bib80">Squire, 2005</xref>). Mutations in sarcomeric proteins are linked to congenital human cardiac and skeletal muscle diseases (<xref ref-type="bibr" rid="bib10">Bönnemann and Laing, 2004</xref>; <xref ref-type="bibr" rid="bib61">Parker et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Parker and Peckham, 2020</xref>). Although the overall structures of sarcomeres are well-established and the protein components of sarcomeres are largely known, it remains controversial how sarcomeres correctly assemble in vivo. Several different but not mutually exclusive models including the template model, the stitching model, and the premyofibril model have been proposed (<xref ref-type="bibr" rid="bib49">Martin and Kirk, 2020</xref>; <xref ref-type="bibr" rid="bib73">Rui et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Sanger et al., 2006</xref>). The template model proposes that actin stress fibers serve as an early template to recruit other sarcomeric components including Z-disc proteins and the thin and thick filaments (<xref ref-type="bibr" rid="bib21">Dlugosz et al., 1984</xref>). The stitching model or the titin model proposes that the actin filaments held by the Z-disc (i.e. the I-Z-I complexes) and the myosin filaments first assemble independently, and they are then stitched together to form intact sarcomeres with the help of titin as titin is known to simultaneously interact with Z-disc proteins via its N-terminal region and M-line proteins via its C-terminal region (<xref ref-type="bibr" rid="bib35">Holtzer et al., 1997</xref>; <xref ref-type="bibr" rid="bib44">Lu et al., 1992</xref>). The premyofibril model states that mini-sarcomeres consisting of actin filaments, α-actinin-containing Z bodies, and non-muscle myosin IIs first assemble near cell periphery. Then, non-muscle myosin IIs are replaced by muscle myosin II during the transition from premyofibrils to nascent myofibrils and finally to mature myofibrils (<xref ref-type="bibr" rid="bib68">Rhee et al., 1994</xref>; <xref ref-type="bibr" rid="bib74">Sanger et al., 2006</xref>). Each of these models is supported by some experimental observations but may be incompatible with others (<xref ref-type="bibr" rid="bib14">Chopra et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Rui et al., 2010</xref>). In addition, mechanical tension generated by attachment of myofibers to tendon, myofiber bundling, and formation of mini-sarcomeres is also found to promote sarcomere assembly in both fly and mammalian muscle cells (<xref ref-type="bibr" rid="bib14">Chopra et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Loison et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Luis and Schnorrer, 2021</xref>; <xref ref-type="bibr" rid="bib48">Mao et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Weitkunat et al., 2014</xref>).</p><p>Protein phosphatases are a family of enzymes that catalyze the removal of the phosphate group from covalently-linked substrates including proteins, lipids, nucleic acids, and polysaccharides (<xref ref-type="bibr" rid="bib1">Alonso et al., 2004</xref>; <xref ref-type="bibr" rid="bib84">Tonks, 2006</xref>; <xref ref-type="bibr" rid="bib87">Weinfeld et al., 2011</xref>; <xref ref-type="bibr" rid="bib94">Worby et al., 2006</xref>). They antagonize the actions of kinases and regulate various biological processes including tissue development, cell proliferation, differentiation, and cell migration. Interestingly, some of the protein phosphatases are found to be catalytically inactive due to the absence of essential amino acid residues such as the catalytic cysteine in an otherwise well-conserved phosphatase domain (<xref ref-type="bibr" rid="bib11">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="bib67">Reiterer et al., 2020</xref>). These confirmed or putative catalytically inactive phosphatases are also called pseudophosphatases. Although catalytically inactive, several pseudophosphatases are found to play important roles in various organisms (<xref ref-type="bibr" rid="bib5">Azzedine et al., 2003</xref>; <xref ref-type="bibr" rid="bib13">Cheng et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Hinton, 2020</xref>; <xref ref-type="bibr" rid="bib66">Reiterer et al., 2017</xref>). For example, Styx and Sbf1, both members of the pseudophosphatase family, were found to regulate sperm development. Loss of Styx or Sbf1 resulted in male infertility in mice (<xref ref-type="bibr" rid="bib26">Firestein et al., 2002</xref>; <xref ref-type="bibr" rid="bib93">Wishart and Dixon, 2002</xref>).</p><p>In our current study, we identified Styxl2 (previously named as Dusp27), a poorly characterized pseudophosphatase, as a new regulator involved in sarcomere assembly in both zebrafish and mice. The original name of the gene and its protein product (i.e. Dusp27) has caused confusion in the literature due to the fact that the same name was once used for Dupd1 (now re-named as Dusp29), a catalytically active phosphatase (<xref ref-type="bibr" rid="bib27">Friedberg et al., 2007</xref>). Recently, it was proposed that Dusp27 be re-named as Serine/threonine/tyrosine-interacting-like 2 (Styxl2) (<xref ref-type="bibr" rid="bib17">Cooper and Waddell, 2020</xref>). To avoid further confusion, we will use Styxl2 hereafter. Styxl2 is specifically expressed in vertebrate striated muscles. Our work in both zebrafish and mouse models shows that it plays an important role in de novo sarcomere assembly instead of sarcomere maintenance. Mechanistically, we found that Styxl2 directly interacts with non-muscle myosin IIs that are involved in the early stage of sarcomere assembly and subsequently replaced by muscle myosin IIs in mature sarcomeres (<xref ref-type="bibr" rid="bib86">Wang et al., 2018</xref>). Styxl2 promotes ubiquitination and autophagy-dependent degradation of non-muscle myosin IIs, which ultimately facilitates sarcomere assembly in vivo.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Styxl2</italic> encodes a striated muscle-specific pseudophosphatase and is a transcriptional target of the Jak1-Stat1 pathway in myoblasts</title><p>We previously reported that the Jak1-Stat1 pathway plays an important role in myogenic differentiation in cultured myoblasts (<xref ref-type="bibr" rid="bib81">Sun et al., 2007</xref>). However, it remains unclear what genes are targeted by the pathway. To examine the changes in transcriptomes, we conducted a microarray analysis in C2C12 myoblasts: cells were first transfected with either a control siRNA or specific siRNAs targeting <italic>Jak1</italic> or <italic>Stat1</italic> and the cells were harvested at two different time points: (1) after 24 hr of growth in the growth medium (GM 24 hr, the proliferation stage); (2) after 12 hr in the differentiation medium following 24 hr of growth in the GM (DM 12 hr, the early differentiation stage). The total mRNA was extracted and subjected to microarray analysis. Among differentially expressed genes (DEGs) in cells transfected with <italic>Jak1</italic>-siRNA and <italic>Stat1</italic>-siRNA, many were shared, which was expected as both Jak1 and Stat1 function in the same pathway. Some representative targets shared by Jak1 and Stat1 were shown (<xref ref-type="table" rid="table1">Table 1</xref>). Consistent with our previous findings (<xref ref-type="bibr" rid="bib81">Sun et al., 2007</xref>), <italic>myogenin</italic> gene was negatively regulated by both Jak1 and Stat1. Among the genes targeted by both Jak1 and Stat1, <italic>serine/threonine/tyrosine-interacting-like 2</italic> (<italic>Styxl2</italic>), previously also named as <italic>dual-specificity phosphatase 27 (putative</italic>) (<italic>Dusp27</italic>), attracted our attention: it is a poorly characterized gene with only one published report in zebrafish so far (<xref ref-type="bibr" rid="bib25">Fero et al., 2014</xref>). It encodes a member of the dual-specificity phosphatase family with a conserved dual-specificity phosphatase catalytic (DSPc) domain located at its N-terminus (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). However, Styxl2 is predicted to be catalytically inactive due to substitution of a highly-conserved catalytic cysteine by serine in its DSPc domain (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), thus making it a member of the pseudophosphatase subfamily (<xref ref-type="bibr" rid="bib33">Hinton, 2019</xref>; <xref ref-type="bibr" rid="bib38">Kharitidi et al., 2014</xref>). By both RT-qPCR and Western blot, we confirmed that both the mRNA and protein levels of <italic>Styxl2</italic> were induced by siRNAs against <italic>Jak1</italic> or <italic>Stat1</italic> in C2C12 myoblasts, with the extent of induction being more obvious during early differentiation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B and C</xref>). Consistently, treatment of C2C12 myoblasts with leukemia inhibitory factor (LIF) or oncostatin M (OSM), two cytokines that are known to potently activate the Jak1-Stat1 pathway in myoblasts (<xref ref-type="bibr" rid="bib81">Sun et al., 2007</xref>; <xref ref-type="bibr" rid="bib95">Xiao et al., 2011</xref>), indeed led to a gradual decrease of Styxl2 protein (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D and E</xref>). By Western blot, we found that <italic>Styxl2</italic> has a very limited tissue distribution pattern: it is specifically expressed in striated muscles including the heart and skeletal muscles (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Consistently, the expression of <italic>Styxl2</italic> mRNA is confined to the heart and somites of early mouse embryos (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). In C2C12 myoblasts, Styxl2 protein was already present in proliferating myoblasts but was further induced during myogenic differentiation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). We also examined the subcellular localization of Styxl2 in myoblasts. As our home-made polyclonal antibody is not suitable for immunostaining of the endogenous Styxl2, we examined subcellular localization of Flag- or HA-tagged Styxl2 instead in C2C12 cells by immunostaining. We found that both Flag- and HA-tagged Styxl2 were predominantly localized in the cytoplasm (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). Collectively, Styxl2 is a cytoplasmic protein that is specifically expressed in striated muscles.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Candidate genes regulated by both Jak1 and Stat1.</title><p>Selected candidate genes targeted by both si-Jak1 and si-Stat1 were shown. The fold change was determined by the relative levels of a gene in cells treated with si-Jak1 or si-Stat1 over that in control cells. Genes with fold change &gt;1.5 for si-Jak1 and &gt;2 for si-Stat1 were listed in this table. Genes with positive fold change are up-regulated (positive value), while those with negative fold change are down-regulated (negative value). P Stage and D Stage denote the proliferation stage (growth medium. GM 24 hr) and early differentiation stage (differentiation medium, DM 12 hr), respectively.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="3">Probe set ID</th><th align="left" valign="top" rowspan="3">Gene</th><th align="left" valign="top" colspan="4">Fold change</th></tr><tr><th align="left" valign="top" colspan="2">P Stage</th><th align="left" valign="top" colspan="2">D Stage</th></tr><tr><th align="left" valign="top">siJak1</th><th align="left" valign="top">siStat1</th><th align="left" valign="top">siJak1</th><th align="left" valign="top">siStat1</th></tr></thead><tbody><tr><td align="left" valign="top">1417889_at</td><td align="left" valign="top">apolipoprotein B editing complex 2</td><td align="left" valign="top">1.53</td><td align="left" valign="top">4.43</td><td align="left" valign="top">2.43</td><td align="left" valign="top">4.07</td></tr><tr><td align="left" valign="top">1419391_at</td><td align="left" valign="top">myogenin</td><td align="left" valign="top">4.29</td><td align="left" valign="top">9.99</td><td align="left" valign="top">2.62</td><td align="left" valign="top">4.26</td></tr><tr><td align="left" valign="top">1422088_at</td><td align="left" valign="top">v-myc myelocytomatosis viral oncogene homolog 1</td><td align="left" valign="top">2.12</td><td align="left" valign="top">3.9</td><td align="left" valign="top">1.88</td><td align="left" valign="top">3.68</td></tr><tr><td align="left" valign="top">1422606_at</td><td align="left" valign="top">C1q and tumor necrosis factor related protein 3</td><td align="left" valign="top">2.23</td><td align="left" valign="top">13.4</td><td align="left" valign="top">1.68</td><td align="left" valign="top">5.45</td></tr><tr><td align="left" valign="top">1426971_at</td><td align="left" valign="top">ubiquitin-activating enzyme E1-like</td><td align="left" valign="top">3.53</td><td align="left" valign="top">7.05</td><td align="left" valign="top">2.42</td><td align="left" valign="top">3.03</td></tr><tr><td align="left" valign="top">1427306_at</td><td align="left" valign="top">ryanodine receptor 1</td><td align="left" valign="top">2.11</td><td align="left" valign="top">6</td><td align="left" valign="top">2.71</td><td align="left" valign="top">4.52</td></tr><tr><td align="left" valign="top">1449178_at</td><td align="left" valign="top">PDZ and LIM domain 3</td><td align="left" valign="top">3.45</td><td align="left" valign="top">12.3</td><td align="left" valign="top">2.94</td><td align="left" valign="top">7</td></tr><tr><td align="left" valign="top">1451453_at</td><td align="left" valign="top">death-associated kinase 2</td><td align="left" valign="top">1.52</td><td align="left" valign="top">3.14</td><td align="left" valign="top">1.96</td><td align="left" valign="top">3.81</td></tr><tr><td align="left" valign="top">1452520_a_at</td><td align="left" valign="top">cholinergic receptor</td><td align="left" valign="top">6.76</td><td align="left" valign="top">15.5</td><td align="left" valign="top">2.6</td><td align="left" valign="top">4.13</td></tr><tr><td align="left" valign="top">1429223_a_at</td><td align="left" valign="top">hemochromatosis type 2 (juvenile) (human homolog)</td><td align="left" valign="top">2.16</td><td align="left" valign="top">28.8</td><td align="left" valign="top">2</td><td align="left" valign="top">7.66</td></tr><tr><td align="left" valign="top">1429459_at</td><td align="left" valign="top">sema domain</td><td align="left" valign="top">2.77</td><td align="left" valign="top">4.43</td><td align="left" valign="top">2.27</td><td align="left" valign="top">5.58</td></tr><tr><td align="left" valign="top">1435828_at</td><td align="left" valign="top">avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog</td><td align="left" valign="top">1.96</td><td align="left" valign="top">3.38</td><td align="left" valign="top">1.63</td><td align="left" valign="top">3.27</td></tr><tr><td align="left" valign="top">1439658_at</td><td align="left" valign="top">leiomodin 3 (fetal)</td><td align="left" valign="top">1.91</td><td align="left" valign="top">17.9</td><td align="left" valign="top">2.83</td><td align="left" valign="top">18.8</td></tr><tr><td align="left" valign="top">1439746_at</td><td align="left" valign="top">dual specificity phosphatase 27 (putative) (dusp27)</td><td align="left" valign="top">1.82</td><td align="left" valign="top">4.78</td><td align="left" valign="top">1.73</td><td align="left" valign="top">2.36</td></tr><tr><td align="left" valign="top">1444494_at</td><td align="left" valign="top">kelch repeat and BTB (POZ) domain containing 10</td><td align="left" valign="top">2.46</td><td align="left" valign="top">9.63</td><td align="left" valign="top">2.79</td><td align="left" valign="top">6.38</td></tr><tr><td align="left" valign="top">1421426_at</td><td align="left" valign="top">Hedgehog-interacting protein</td><td align="left" valign="top">–2.04</td><td align="left" valign="top">–3.55</td><td align="left" valign="top">–1.62</td><td align="left" valign="top">–6.65</td></tr><tr><td align="left" valign="top">1435438_at</td><td align="left" valign="top">SRY-box containing gene 8 (sox8)</td><td align="left" valign="top">1.85</td><td align="left" valign="top">4.01</td><td align="left" valign="top">1.51</td><td align="left" valign="top">5.7</td></tr></tbody></table></table-wrap><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Styxl2 regulates sarcomere integrity during zebrafish muscle development.</title><p>(<bold>A</bold>) A schematic of mouse Styxl2 protein. DSPc (red): dual-specificity phosphatase, catalytic domain. The numbers denote the positions of various amino acids in mouse Styxl2 including Ser (S) –225. (<bold>B</bold>) The expression of Styxl2 protein in different mouse tissues. 100 μg of soluble mouse tissue lysates were subjected to Western blot analysis. GAPDH: glyceraldehyde-3-phosphate dehydrogenase. SM: skeletal muscles. (<bold>C</bold>) The expression of Styxl2 protein in C2C12 myoblasts before and after differentiation in culture. MHC: myosin heavy chain. (<bold>D</bold>) Zebrafish zygotes were either mock-injected or injected with a Styxl2-specific morpholino (MO). Sarcomeres in muscles at 48 hpf were revealed by transmission electron microscopy (TEM). Representative images were shown. Scale bar: 500 nm. (<bold>E</bold>) Sarcomeres in fast and slow muscles of zebrafish embryos at 24 hpf were revealed by immunostaining using specific antibodies as indicated. Ctrl: control (non-treated); MO: <italic>Styxl2</italic>-morpholino-treated. The nuclei of slow and fast muscle fibers were counter-stained with an anti-Prox1 antibody and DAPI, respectively. Scale bar: 10 μm.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig1">Figure 1B</xref> (anti-Styxl2 and anti-GAPDH).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig1">Figure 1B</xref> (anti-Styxl2 and anti-GAPDH) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig1">Figure 1C</xref> (anti-MHC, anti-Styxl2, and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig1">Figure 1C</xref> (anti-MHC, anti-Styxl2, and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Styxl2 was downstream target of Jak1-Stat1 pathway.</title><p>(<bold>A</bold>) Multiple sequence alignment of the region surrounding the active motif of the dual-specificity phosphatase catalytic (DSPc) domain among mouse dual-specificity phosphatases and Styxl2. The conserved Cys in functional phosphatases was highlighted in yellow. (<bold>B, C</bold>) C2C12 cells were transfected with various siRNAs as indicated. After growing in growth medium (GM) for 24 hr (h), cells were harvested either right away (GM 24 h) or after growing in differentiation medium (DM) for an additional 12 hr (DM 12 h). The total RNA and soluble whole cell lysates were subjected to RT-qPCR (<bold>B</bold>) or Western blot analysis (<bold>C</bold>), respectively. (<bold>D, E</bold>) C2C12 cells were treated with 10 ng/ml of leukemia inhibitory factor (LIF) or oncostatin M (OSM) for various times. Cell extracts were subjected to Western blot analysis. (<bold>F</bold>) Mouse embryos at E9.5 and E10.5 were subjected to in situ hybridization using either sense (control) or antisense probe specific for mouse <italic>Styxl2</italic>. (<bold>G</bold>) C2C12 cells were transfected with constructs expressing Flag- or HA-tagged Styxl2 for 24 hr. Cells were then fixed and subjected to immunostaining for Flag or HA. (<bold>H</bold>) Zebrafish zygotes were co-injected with a plasmid encoding GFP fused with the sequence targeted by <italic>Styxl2</italic>-morpholino oligo (MO) at the start codon together with or without <italic>Styxl2</italic>-MO. The phase-contrast and fluorescent images were taken and the representative images were shown.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref> (anti-Jak1, anti-Stat1, anti-Styxl2, and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref> (anti-Jak1, anti-Stat1, anti-Styxl2, and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref> (anti-Styxl2).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata4"><label>Figure 1—figure supplement 1—source data 4.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D and E</xref> (anti-Tubulin in D, anti-Styxl2, and anti-Tubulin in E).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata5"><label>Figure 1—figure supplement 1—source data 5.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D and E</xref> (anti-Styxl2 and anti-Tubulin in D, anti-Styxl2, and anti-Tubulin in E) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig1-figsupp1-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Knockdown of <italic>Styxl2</italic> in zebrafish leads to severe defects in sarcomere structure</title><p>An earlier study by <xref ref-type="bibr" rid="bib25">Fero et al., 2014</xref> in zebrafish showed that Styxl2 regulates the integrity of sarcomeres. We also confirmed this finding in zebrafish using a morpholino oligo (MO) that blocks the translation initiation of <italic>Styxl2</italic>. The effectiveness of the MO was verified using a transgene encoding green fluorescence protein (GFP) fused in-frame with the same sequence of <italic>Styxl2</italic> (i.e. the first 25 nucleotides of the coding region) targeted by the MO: when zebrafish zygotes were microinjected with the transgenes with or without the MO, the expression of GFP was suppressed only when the MO was co-injected (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). We then injected zebrafish zygotes with or without the <italic>Styxl2</italic>-MO and examined the structures of skeletal muscles by immunostaining at 24 hr after fertilization (hpf). Consistent with the report by <xref ref-type="bibr" rid="bib25">Fero et al., 2014</xref>, we found that sarcomeres in both fast and slow muscles were severely disrupted when <italic>Styxl2</italic> was knocked down with the MO (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Moreover, electron microscopy analysis further revealed the disrupted sarcomere structures in zebrafish muscles injected with the MO (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p></sec><sec id="s2-3"><title>Conditional deletion of <italic>Styxl2</italic> leads to neonatal lethality in mutant mice</title><p>To further explore the role of Styxl2 in mammals, we generated <italic>Styxl2</italic> floxed mice with two LoxP sites flanking exons 3~5 of the <italic>Styxl2</italic> gene (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Exons 4 and 5 encode a part of the DSPc domain of Styxl2. We first generated germline <italic>Styxl2</italic> knockout (KO) mice using EIIA-Cre mice (<xref ref-type="bibr" rid="bib41">Lakso et al., 1996</xref>). Western blot analysis showed that Styxl2 protein was totally absent in KO mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). In multiple litters, no live homozygous KO pups were found after birth (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). By examining developing embryos of different ages, we found that <italic>Styxl2</italic> KO embryos died between E13.5 and E15.5 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). In some dead <italic>Styxl2</italic> KO fetuses, edema was found (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), suggesting potential problems with the heart (<xref ref-type="bibr" rid="bib16">Conway et al., 2003</xref>). This is consistent with the fact that Styxl2 is also highly expressed in cardiac muscles as well. The electron microscopy analysis of the heart muscles from E14.5 embryos revealed that the sarcomeric structures of cardiac muscles from <italic>Styxl2</italic> KO embryos were severely disrupted (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). To focus on the functions of Styxl2 in skeletal muscles, we generated conditional <italic>Styxl2</italic> KO (CKO) mice by crossing <italic>Styxl2<sup>f/f</sup></italic> mice with <italic>Pax7<sup>Cre/+</sup></italic> mice (<xref ref-type="bibr" rid="bib37">Keller et al., 2004</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). We found that <italic>Styxl2</italic> CKO pups were born at the expected Mendelian ratio but all the homozygous mutant pups died in a few hours after birth (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). As Pax7 is also expressed in other non-muscle cell types including neurons during embryo development, to be certain that embryonic lethality of <italic>Pax7<sup>Cre/+</sup>; Styxl2<sup>f/f</sup></italic> mice was indeed caused by severe defects in skeletal muscles, we also specifically deleted <italic>Styxl2</italic> in skeletal muscles using a <italic>Myf5<sup>Cre</sup></italic> line in which the <italic>Cre</italic> gene was inserted in the <italic>Myf5</italic> locus (<xref ref-type="bibr" rid="bib82">Tallquist et al., 2000</xref>). Consistently, all skeletal muscle-specific <italic>Styxl2</italic> KO pups died within one day after birth (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Conditional deletion of mouse <italic>Styxl2</italic> leads to defective sarcomeres in striated muscles.</title><p>(<bold>A</bold>) The expression of Styxl2 protein in skeletal muscles of wild-type (+/+), heterozygous (+/−), and <italic>Styxl2</italic> knockout (KO) (−/−) (driven by <italic>EIIA</italic>-Cre) mice. Soluble tissue lysates from limbs of E14.5 mouse embryos were subjected to Western blot analysis. N.S.: non-specific. (<bold>B</bold>) E14.5 embryos of control (Ctrl) and <italic>EIIA</italic>-Cre; <italic>Styxl2<sup>f/f</sup></italic> KO mice. *: edema was found in some <italic>Styxl2</italic> KO foetuses. (<bold>C</bold>) The sarcomere structures of cardiomyocytes in the heart of E14.5 embryos from control and <italic>EIIA</italic>-Cre; <italic>Styxl2<sup>f/f</sup></italic> KO mice were revealed by transmission electron microscopy (TEM). Scale bar: 1 μm. (<bold>D</bold>) The expression of Styxl2 protein in skeletal muscles of control (Ctrl) and <italic>Styxl2</italic> CKO P1 mice. (<bold>E</bold>) The new-born pups (P1) from control (Ctrl) and <italic>Pax7</italic><sup>Cre/+</sup>; <italic>Styxl2<sup>f/f</sup></italic> KO mice (CKO). (<bold>F</bold>) Lung sections of control and Styxl2 CKO P1 mice. Scale bar: 50 μm. (<bold>G</bold>) The sarcomere structure of diaphragm muscles from control (Ctrl) and <italic>Styxl2</italic> conditional KO (CKO) P1 mice revealed by TEM. Scale bar: 1 μm.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig2">Figure 2A</xref> (anti-Styxl2 and N.S.).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig2">Figure 2A</xref> (anti-Styxl2 and N.S.) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig2">Figure 2D</xref> (anti-Styxl2 and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig2-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig2">Figure 2D</xref> (anti-Styxl2 and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig2-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Both germline and conditional deletion of <italic>Styxl2</italic> caused lethality.</title><p>(<bold>A</bold>) The schematic of the genomic locus of mouse <italic>Styxl2</italic> and the targeting strategy. The probes used for Southern blot are indicated by black bars. (<bold>B, C</bold>) The schematic of the mating strategy to generate <italic>Styxl2</italic> germ-line knockout (KO) mice was shown (<bold>B</bold>). The number of live pups (<bold>B</bold>) and that of embryos (<bold>C</bold>) of different genotypes at different embryonic stages were counted and presented. (<bold>D</bold>) The schematic of the mating strategy to generate conditional <italic>Styxl2</italic> KO mice and the number of live pups (in brackets) older than 1 day were shown. (<bold>E</bold>) Hindlimb muscle sections from control (Ctrl) and <italic>Styxl2</italic> conditional KO (CKO) P1 mice were subjected to electron microscopy analysis. Scale bar: 1 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig2-figsupp1-v1.tif"/></fig></fig-group><p>As the skin of <italic>Styxl2</italic> CKO pups appeared cyanotic, we speculated that the new-born mutant mice had lung defects that led to respiratory distress and perinatal death. The lungs of the CKO pups were examined and we found that the pulmonary alveoli indeed failed to open (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), which was likely caused by defective diaphragm muscle as defects in a number of myogenic genes exhibited similar perinatal lethality (<xref ref-type="bibr" rid="bib31">Hasty et al., 1993</xref>; <xref ref-type="bibr" rid="bib72">Rudnicki et al., 1993</xref>). Electron microscopy analysis confirmed that the sarcomere structure was severely disrupted in diaphragm muscle of the mutant mice (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Consistently, electron microscopy revealed that the sarcomere structure of the limb muscle was also severely disrupted (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). Notably, some sarcomeres were still present in the skeletal muscles of the CKO mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>), suggesting that Styxl2 is important but not absolutely required for the formation of the sarcomeres. Therefore, Styxl2 plays an important role in the development of striated muscles, including the skeletal muscle and the heart muscle.</p></sec><sec id="s2-4"><title>Styxl2 is dispensable for the maintenance of mature sarcomeres but critical for de novo sarcomere assembly in adult skeletal muscles</title><p>Although our data above indicated that Styxl2 plays an important role in regulating sarcomere formation during embryonic skeletal muscle development, it remained unclear whether it was necessary for the maintenance of the sarcomere structure in adult skeletal muscles. To address this question, we generated a tamoxifen (TMX) inducible myofiber-specific <italic>Styxl2</italic> knockout mouse model (also named <italic>Styxl2</italic> MF-iKO hereafter) using Tg (HSA-MerCreMer) (<xref ref-type="bibr" rid="bib52">McCarthy et al., 2012</xref>). In this model, <italic>Styxl2</italic> was efficiently deleted in mature skeletal muscles of adult mice (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). We directly assessed the contractile functions of Styxl2-null muscles. Three weeks after the last TMX injection (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), the gastrocnemius muscle was isolated and the twitch and tetanic force generated by the muscle were measured (<xref ref-type="bibr" rid="bib29">Guo et al., 2016</xref>). No obvious difference in twitch or tetanic force was observed between the control and <italic>Styxl2</italic> MF-iKO muscles (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>), suggesting that Styxl2 is dispensable for the maintenance of existing sarcomeres in adult skeletal muscles. Next, we assessed whether Styxl2 played a role in the de novo formation of nascent sarcomeres in regenerating muscles of adult mice. To do so, we generated another tamoxifen-inducible, MuSC-specific <italic>Styxl2</italic> KO mouse model using <italic>Pax7<sup>CreERT2/CreERT2</sup>; Styxl2<sup>f/f</sup></italic> (also named <italic>Styxl2</italic> SC-iKO mice hereafter) (<xref ref-type="bibr" rid="bib55">Murphy et al., 2011</xref>). <italic>Styxl2</italic> was first deleted in muscle satellite cells (MuSCs) of adult mice according to the scheme in <xref ref-type="fig" rid="fig3">Figure 3E</xref>, followed by acute injury to the hindlimb skeletal muscles with Cardiotoxin (CTX) (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). As injured muscles are repaired by MuSCs, the nascent sarcomeres in regenerating myofibers of <italic>Styxl2</italic> SC-iKO mice would be formed in the absence of Styxl2 (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). At 30 days post-injury, a time point when injured muscles are known to be fully regenerated (<xref ref-type="bibr" rid="bib23">Dumont et al., 2015</xref>), the gastrocnemius muscles were isolated and functionally tested in vitro. Both the twitch and tetanic force were measured separately. Compared to muscles from the control mice, the twitch force generated by muscles from <italic>Styxl2</italic> SC-iKO mice was decreased by ~30% (<xref ref-type="fig" rid="fig3">Figure 3G</xref>), while the tetanic force generated by muscles from the mutant mice was not affected (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). This suggested that sarcomeres formed de novo in regenerating myofibers from Styxl2-null MuSCs were partially defective. When we examined sarcomeres by electron microscopy, we noticed that the length of individual sarcomeres from <italic>Styxl2</italic> SC-iKO mice was shorter in regenerated muscles (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>). Thus, our data showed that Styxl2 functions in de novo sarcomere assembly in regenerating muscles from adult mice.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Styxl2 is not required for sarcomere maintenance but involved in de novo sarcomere assembly in adult muscles.</title><p>(<bold>A</bold>) The schematic to assess the role of Styxl2 in sarcomere maintenance in adult muscles. TMX: tamoxifen. (<bold>B</bold>) Styxl2 protein levels in control (Ctrl) and myofiber-specific <italic>Styxl2</italic> knockout (MF-iKO) mouse gastrocnemius muscles used for force test. The band intensity of Styxl2 was quantified by ImageJ. (<bold>C, D</bold>) The twitch and tetanic force generated by gastrocnemius muscles of three Ctrl and four MF-iKO mice were measured. In (<bold>A–D</bold>), Ctrl: <italic>Styxl2<sup>f/f</sup></italic> mice; MF-iKO: <italic>Tg: HSA-MerCreMer; Styxl2<sup>f/f</sup></italic> mice. (<bold>E</bold>) The schematic to assess the role of Styxl2 in de novo sarcomere assembly in adult muscles. CTX: cardiotoxin. (<bold>F</bold>) Styxl2 protein levels in regenerated gastrocnemius muscles used for force test. N.S.: non-specific. The band intensity of Styxl2 was quantified. (<bold>G, H</bold>) Twitch and tetanic force by regenerated gastrocnemius muscles were measured from four pairs of control and MuSC-specific <italic>Styxl2</italic> KO (SC-iKO) mice. (<bold>I</bold>) Transmission electron microscopy (TEM) images of the muscle used for force generation test. Scale bar: 500 nm. (<bold>J</bold>) Quantification of sarcomere length in (<bold>I</bold>). TEM images from three pairs of mice were examined and the length of 3–5 sarcomeres from each mouse was measured. In (<bold>E–J</bold>), Ctrl: <italic>Pax7<sup>CreERT2/CreERT2</sup></italic> mice; SC-iKO: <italic>Pax7<sup>CreERT2/CreERT2</sup>; Styxl2<sup>f/f</sup></italic> mice. n.s.: not significant. *p-value &lt;0.05. ***p-value &lt;0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig3">Figure 3B</xref> (anti-Styxl2 and Loading).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig3">Figure 3B</xref> (anti-Styxl2 and Loading) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig3">Figure 3F</xref> (anti-Styxl2 and N.S.).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig3-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig3">Figure 3F</xref> (anti-Styxl2 and N.S.) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig3-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig3-v1.tif"/></fig></sec><sec id="s2-5"><title>Styxl2 directly binds to non-muscle myosin II (NM II) in myoblasts</title><p>To understand how Styxl2 functions to regulate sarcomere formation, we employed BioID, a proximity-dependent protein labelling method (<xref ref-type="bibr" rid="bib70">Roux et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Roux et al., 2018</xref>), to search for binding partners of Styxl2. The full-length Styxl2 was fused in-frame with BirA*, a mutant form of biotin ligase BirA (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The fused gene encoding Styxl2-BirA*-HA was stably expressed in C2C12 myoblasts using the Tet-on system (<xref ref-type="bibr" rid="bib20">Das et al., 2016</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). As Styxl2 is expected to function during late myogenic differentiation, we followed the scheme in <xref ref-type="fig" rid="fig4">Figure 4B</xref> and added biotin into the culture medium with or without doxycycline (Dox) for 24 hr before harvest. By Western blot, we showed that Styxl2-BirA*-HA was strongly induced by Dox as expected (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>, middle panel). Importantly, more cellular proteins were biotinylated in Styxl2-BirA*-HA-expressing cells induced by Dox (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>, top panel). These biotinylated proteins were isolated and enriched by streptavidin beads and analysed by iTRAQ-based mass spectrometry (<xref ref-type="bibr" rid="bib91">Wiese et al., 2007</xref>). The biotinylated proteins enriched in Styxl2-BirA*-HA-expressing cells (Enrichment score &gt;1) were further analysed by gene ontology (GO) analysis. Notably, a number of the enriched proteins were related to ‘myofibril’, ‘sarcomere’, and ‘A band’ (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). This supports our hypothesis that Styxl2 functions to regulate sarcomere assembly. To help identify direct interaction partners of Styxl2, the log<sub>2</sub> Enrichment scores (i.e. the peak intensity ratios of the reporter ions) were plotted against the minus log<sub>10</sub>(p.values). Those enriched proteins with the Enrichment score &gt;1.2 and p&lt;0.05 were highlighted in red on the plot (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), and some of the enriched proteins (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>) were selected for further confirmation by co-immunoprecipitation (co-IP) assays using lysates from differentiated C2C12 myotubes. Among them, Myh9 and Myh10, the members of the non-muscle myosin IIs (NM IIs) (<xref ref-type="bibr" rid="bib59">Newell-Litwa et al., 2015</xref>), were found to specifically interact with the endogenous Styxl2 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Moreover, by protein truncation analysis in combination with the co-IP assays, we showed that the head domains of Myh9 and Myh10 were responsible for their interaction with Styxl2 (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Styxl2 binds to non-muscle myosin IIs.</title><p>(<bold>A</bold>) The schematic of the fusion protein Styxl2-BirA*-HA. (<bold>B</bold>) The workflow of sample preparation for BioID. (<bold>C</bold>) Enriched (with Enrichment score &gt;1) biotinylated proteins in cells expressing Styxl2-BirA*-HA relative to that in control cells were identified by mass spectrometry followed by Gene Ontology (GO) analysis. Myofibril-related terms were shown. (<bold>D</bold>) C2C12 cells were harvested after 2 days in differentiation medium (DM) and the soluble whole cell lysates were subjected to immunoprecipitation (IP) using either an anti-MEF2A (negative control) or an anti-Styxl2 antibody. The endogenous Myh9 or Myh10 was detected by Western blot. (<bold>E</bold>) The schematic shows the domains of non-muscle myosin IIs (NM II). (<bold>F</bold>) HEK 293T cells were transfected with Flag-Styxl2 (black arrow) together with HA-NM II-head (red arrowheads) or HA-NM II-tail (black arrowheads). The soluble whole cell lysates were subjected to IP with an anti-Flag antibody and the co-immunoprecipitated proteins were detected by Western blot.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original scans for the Western blot analysis of input and IP in <xref ref-type="fig" rid="fig4">Figure 4D</xref> (anti-Styxl2, anti-Myh9, and anti-Myh10).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4D</xref> (anti-Styxl2, anti-Myh9, and anti-Myh10) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original scans for the Western blot analysis of input and IP in <xref ref-type="fig" rid="fig4">Figure 4F</xref> (anti-Flag and anti-HA).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4F</xref> (anti-Flag and anti-HA) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig4-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Identification of Styxl2-interacting partners by BioID.</title><p>(<bold>A</bold>) A representative gel of samples from BioID before mass spectrometry analysis. Whole cell lysates from control (Ctrl) and Doxycycline-treated (Dox) cells were subjected to Western blot using Streptavidin-HRP (top panel) or an anti-Styxl2 antibody (middle panel). (<bold>B</bold>) The biotinylated proteins identified by mass spectrometry were plotted with the log<sub>2</sub>Enrichment scores on the X-axis and the minus log<sub>10</sub>(p.value) on the Y-axis. The Enrichment score denotes the ratio of the peak intensity of reporter ions. Red dots indicate proteins with the Enrichment score &gt;1.2 and p-value &lt;0.05. Blue dots indicate proteins with the Enrichment score &lt;0.83 and p-value &lt;0.05. (<bold>C</bold>) Selected candidate proteins with more than 10 recovered peptides were shown.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref> (Streptavidin-HRP, anti-Styxl2, and Loading).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref> (Streptavidin-HRP, anti-Styxl2, and Loading) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>An Excel file showing raw data of iTRAQ-based mass spectrometry analysis for potential Styxl2 interactors in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig4-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Styxl2 promotes sarcomere assembly by down-regulating NM IIs</title><p>Our data above indicated that Styxl2 regulates sarcomere assembly. NM IIs were reported to participate in sarcomere assembly in several organisms (<xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>; <xref ref-type="bibr" rid="bib75">Sanger et al., 2009</xref>; <xref ref-type="bibr" rid="bib85">Tullio et al., 1997</xref>). However, NM IIs are not detected in mature sarcomeres and their replacement by muscle-specific myosin is a marker of skeletal muscle maturation. Therefore, we examined protein levels of Myh9 and Myh10 in both differentiating C2C12 myotubes and postnatal mouse skeletal muscles over time. In differentiating C2C12 cells, we found that the protein levels of Myh9 and Myh10 slightly increased at the beginning of myogenic differentiation, but started to decrease ~four days after myogenic differentiation, which coincided with the time when the sarcomeric myosin heavy chain started to increase (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). In postnatal mouse skeletal muscles, the protein levels of Myh9 and Myh10 started to drop at P8 and became non-detectable by P30 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), which was consistent with previous reports (<xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>; <xref ref-type="bibr" rid="bib75">Sanger et al., 2009</xref>). The protein levels of Styxl2 remained constant and abundant in the first month after birth but began to drop to a lower level by P65 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). When we examined the protein levels of Myh9 and Myh10 in skeletal muscles of P1 pups, we noticed an obvious increase in protein levels of Myh9 and Myh10 in <italic>Styxl2</italic> CKO mice (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). We also examined protein levels of Myh9 and Myh10 in regenerating adult muscles. Using SC-iKO mice and <italic>Pax7<sup>CreERT2/CreERT2</sup></italic> control mice as described in <xref ref-type="fig" rid="fig3">Figure 3E</xref>, we first induced <italic>Styxl2</italic> deletion by tamoxifen in adult MuSCs followed by BaCl<sub>2</sub>-induced muscle injury. At 7 dpi, the levels of Myh9 and Myh10 were comparable between control and <italic>Styxl2</italic> SC-iKO mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Interestingly, at 10 dpi, Myh9 and Myh10 were nearly undetectable in muscles from control mice, but they remained at a higher level in muscles from <italic>Styxl2</italic> SC-iKO mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Our data above suggested that loss of Styxl2 results in delayed degradation of NM II during sarcomere assembly. To further prove this is the case, we turned to the zebrafish model. It was reported that <italic>Styxl2<sup>-/-</sup></italic> zebrafish exhibited severe motility defects in response to needle touch (<xref ref-type="bibr" rid="bib25">Fero et al., 2014</xref>). Consistently, we also found that <italic>Styxl2</italic> morphants displayed similar phenotypes: most of the <italic>Styxl2</italic> morphants did not respond to the needle touch (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), which was caused by defective sarcomere structures in skeletal muscles (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Knowing that NM IIs are involved in the early phase of sarcomere assembly followed by their replacement with the sarcomeric myosin (<xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">White et al., 2014</xref>), we suspected that delayed degradation of NM IIs was responsible for defective sarcomere structure in <italic>Styxl2</italic> morphants. Therefore, it was likely that simultaneous knockdown of both NM IIs and <italic>Styxl2</italic> may rescue the sarcomeric defects in <italic>Styxl2</italic> morphants. It was reported that both <italic>Myh9b</italic> and <italic>Myh10</italic> are expressed in skeletal muscles of zebrafish (<xref ref-type="bibr" rid="bib30">Gutzman et al., 2015</xref>). When we knocked down <italic>Myh9b</italic> with a MO in <italic>Styxl2</italic> morphants, the embryos died very early before skeletal muscles were formed (our unpublished data). When zebrafish zygotes were co-injected with the <italic>Styxl2</italic>-MO and a MO targeting <italic>Myh10</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), the percentage of fishes responding to the needle touch was obviously increased (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Consistently, the disrupted sarcomere structure caused by <italic>Styxl2</italic>-MO was indeed partially restored in the <italic>Styxl2/Myh10</italic> double-knockdown fishes (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Styxl2 protein levels inversely correlates with that of non-muscle myosin IIs.</title><p>(<bold>A</bold>) Protein levels of Styxl2 and non-muscle myosin IIs in skeletal muscles of wild-type mice of different ages were determined by Western blot. (<bold>B</bold>) Protein levels of Styxl2 and non-muscle myosin IIs in skeletal muscles of control and <italic>Styxl2</italic> conditional KO (CKO) P1 mice were determined by Western blot. (<bold>C</bold>) Relative ratios of non-muscle myosin II protein levels in control and <italic>Styxl2</italic> CKO P1 mice were quantified by ImageJ based on the data from four (for Myh9) or five (for Myh10) sets of Western blots. (<bold>D</bold>) Protein levels of Styxl2 and non-muscle myosin IIs in regenerating tibialis anterior muscles were determined by Western blot. The experiments were done for four times with similar results and a representative gel was shown. The protein levels of NM IIs in 10 dpi muscles revealed by Western blot were quantified in the right panel. Ctrl: <italic>Pax7<sup>CreERT2/CreERT2</sup></italic> mice; SC-iKO: <italic>Pax7<sup>CreERT2/CreERT2</sup>; Styxl2<sup>f/f</sup></italic> mice; dpi: days post-injury. (<bold>E</bold>) Zebrafish zygotes were separately injected with the following morpholinos (MO): control (Ctrl-MO), <italic>Styxl2</italic>-MO, and mixed morpholinos targeting both <italic>Styxl2</italic> and <italic>Myh10</italic> (dMO). At 48 hpf, zebrafishes were poked by a fine needle and their responses were recorded. Quantification of responses of zebrafish to needle touch was shown. In each group, at least eight zebrafishes were tested and the percentage of zebrafishes responding to needle touch was calculated. Each dot represents one group of experiment. (<bold>F</bold>) Zebrafishes from each condition in (<bold>E</bold>) were subjected to immunostaining for α-actinin to visualize sarcomere structures. Representative images were shown. The inset at the top right corner of each image shows the actinin intensity along the yellow line. Scale bar: 10 μm. *p-value &lt;0.05. **p-value &lt;0.01. ****p-value &lt;0.0001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (anti-Styxl2, anti-Myh9, anti-Myh10 and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (anti-Styxl2, anti-Myh9, anti-Myh10, and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5B</xref> (anti-Styxl2, anti-Myh9, anti-Myh10, and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5B</xref> (anti-Styxl2, anti-Myh9, anti-Myh10, and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5D</xref> (anti-Styxl2, anti-Myh9, anti-Myh10, and Loading).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5D</xref> (anti-Styxl2, anti-Myh9, anti-Myh10, and Loading) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The protein levels of NM IIs in differentiating C2C12 cells and the knockdown efficiency of Myh10-MO.</title><p>(<bold>A</bold>) Confluent C2C12 cells were induced to differentiate in differentiation medium (DM) and harvested at different time points. Soluble whole cell lysates were subjected to Western blot analysis. (<bold>B</bold>) Zebrafish zygotes were injected with control (Ctrl) or Myh10-morpholino oligo (MO) and the fish were collected for Western blot analysis at 48 hpf.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref> (anti-MHC, anti-Myh9, anti-Myh10, anti-Styxl2, and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref> (anti-MHC, anti-Myh9, anti-Myh10, anti-Styxl2, and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> (anti-Myh10 and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata4"><label>Figure 5—figure supplement 1—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> (anti-Myh10 and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig5-figsupp1-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Styxl2 induces the degradation of NM IIs via its C-terminal domain</title><p>Our data above showed that loss of Styxl2 caused abnormal accumulation of NM IIs (<xref ref-type="fig" rid="fig5">Figure 5</xref>), which suggested that Styxl2 normally promote degradation of NM IIs during nascent sarcomere assembly. To test whether this is the case, we co-expressed HA-Myh9 with either Mst1 (as a negative control) or Styxl2 in C2C12 myoblasts. The protein levels of HA-Myh9 were indeed reduced by co-transfected Styxl2 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We further found that Styxl2-mediated reduction in Myh9 protein levels was not caused by reduced <italic>Myh9</italic> mRNA (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). To determine which part of Styxl2 promotes degradation of NM IIs, we truncated Styxl2 into two fragments (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, upper panel): an N-terminal fragment containing the DSPc domain (i.e. aa 1–513, also termed Styxl2N513 hereafter) and a C-terminal fragment without the DSPc domain (i.e. aa 510–1138, also named Styxl2ΔN509 hereafter). When we co-transfected 293T cells with a construct encoding HA-Myh9 together with another construct encoding Mst1, Styxl2N513, or Styxl2ΔN509, we found that only Styxl2ΔN509 promoted degradation of Myh9 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, lane 3). As we previously showed that the head domains of NM IIs were involved in interacting with Styxl2 (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>), we then tested whether the protein levels of the head domain of Myh9 were also regulated by Styxl2. Consistently, only Styxl2ΔN509 promoted degradation of the head domain of Myh9 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, lane 6). To further verify this finding in vivo, we microinjected the mRNA encoding the full-length or the C-terminus of zebrafish Styxl2 (zStyxl2), along with the MO for z<italic>Styxl2</italic>, into the zebrafish one-cell embryos. As expected, the defective sarcomere structure caused by <italic>zStyxl2</italic> knockdown was efficiently rescued by overexpressing the mRNA encoding the full-length zStyxl2, as revealed by the α-actinin staining (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Importantly, the mRNA encoding the C-terminus of zStyxl2 was nearly as effective as that encoding the full-length zStyxl2 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Similar results were also obtained when we subjected fish to myosin staining (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Thus, the C-terminus of Styxl2, without the DSPc domain, is both necessary and sufficient to promote degradation of NM IIs during nascent sarcomere assembly.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The dual-specificity phosphatase catalytic (DSPc) domain of Styxl2 is dispensable for degradation of non-muscle myosin IIs.</title><p>(<bold>A</bold>) DNA constructs encoding Myh9, Styxl2, or Mst1 (negative control) were co-expressed in C2C12 cells. Soluble whole cell extracts were subjected to Western blot analysis. OE: overexpression. (<bold>B</bold>) The schematic shows the truncated fragments of Styxl2 protein. The red blocks indicate the DSPc domain of Styxl2. HEK 293T cells were transfected with different plasmids as indicated. 24 hr after transfection, cells were harvested, and soluble whole cell extracts were subjected to Western blot analysis. The arrow indicates the head domain of Myh9, and the arrowhead indicates Styxl2 missing the N-terminal 509 aa (Styxl2ΔN509). Mst1: negative control. N.S.: non-specific. (<bold>C</bold>) Zebrafish zygotes were injected with various morpholinos as indicated with or without the co-injected <italic>Styxl2</italic> mRNAs. z<italic>Styxl2</italic>FL: the full-length fish <italic>Styxl2</italic> mRNA; z<italic>Styxl2</italic>ΔN493: the truncated fish <italic>Styxl2</italic> mRNA missing the 5’ region encoding the N-terminal 493 aa. Representative α-actinin immunofluorescent images were shown. The number in numerator at the top left corner of each image represents fish embryos showing normal α-actinin staining pattern, while that in denominator represents the total number of embryos examined. The inset at the top right corner of each image shows the actinin intensity along the yellow line. Scale bar: 10 μm.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig6">Figure 6A</xref> (anti-Flag, anti-HA, and N.S.).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig6">Figure 6A</xref> (anti-Flag, anti-HA, and N.S.) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig6">Figure 6B</xref> (anti-Flag, anti-HA, and N.S.).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig6-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig6">Figure 6B</xref> (anti-Flag, anti-HA, and N.S.) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig6-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Styxl2 regulates the protein levels of NM IIs without affecting their mRNA.</title><p>(<bold>A</bold>) Control (Ctrl) or Styxl2 DNA constructs were transfected into C2C12 cells. 24 hr later, the mRNA levels of different genes were determined by qPCR. **p-value &lt;0.01. n.s.: not significant. (<bold>B</bold>) Zebrafish zygotes were injected with various morpholinos as indicated with or without the co-injected <italic>Styxl2</italic> mRNAs. z<italic>Styxl2</italic>FL: the full-length fish <italic>Styxl2</italic> mRNA; z<italic>Styxl2</italic>ΔN493: the truncated fish <italic>Styxl2</italic> mRNA missing the 5’ region encoding the N-terminal 493 aa. Representative immunofluorescent images of myosin heavy chain (MHC) were shown. The number in numerator at the top right corner of each image represents fish embryos showing normal MHC staining pattern, while that in denominator represents the total number of embryos examined. Scale bar: 10 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-8"><title>Styxl2 promotes the degradation of NM IIs via the autophagy-lysosome pathway</title><p>In order to understand how Styxl2 promotes the degradation of NM IIs, we first turned to the ubiquitination/proteasome pathway (<xref ref-type="bibr" rid="bib58">Nandi et al., 2006</xref>). MG132, a specific proteasome inhibitor, was added to C2C12 cells transfected with Styxl2. No abnormal accumulation of NM IIs was found in the presence of MG132 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), suggesting that the proteasome is not involved in Styxl2-mediated degradation of NM IIs. Next, we turned to the autophagy-lysosome-dependent protein degradation system. In C2C12 myoblasts, we co-expressed Myh9 with either Mst1 (control) or Styxl2 together with an siRNA against GFP (control) or ATG5, a key component of the autophagy pathway (<xref ref-type="bibr" rid="bib53">Mizushima et al., 2010</xref>). In the presence of the control siRNA, Styxl2 efficiently promoted degradation of Myh9 as expected (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, lane 2). However, in the presence of ATG5 siRNA, the protein levels of Myh9 were restored to levels comparable to that of the control even in the presence of the co-expressed Styxl2 (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, lane 3). This result supported the involvement of the autophagy pathway in Styxl2-mediated degradation of NM IIs. Furthermore, we also examined the degradation of Myh9 induced by Styxl2Δ509 with or without several different autophagy inhibitors (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). In the absence of any autophagy inhibitors, Styxl2ΔN509 induced degradation of Myh9 as expected (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, lanes 3 and 4). In the presence of LY294002 (an inhibitor of PI3K), chloroquine (an inhibitor that blocks the binding of autophagosomes to lysosomes), bafilomycin A1 (BafA1, an inhibitor of V-ATPase that can block autophagic flux), and NH<sub>4</sub>Cl (an inhibitor of the degradative enzymes inside lysosomes), the protein levels of Myh9 were largely restored to the levels comparable to that in the controls (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, lanes 1 and 2). Thus, we concluded that the autophagy-lysosome pathway is involved in the degradation of NMIIs induced by Styxl2.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>The Styxl2-mediated degradation of non-muscle myosin IIs is autophagy dependent.</title><p>(<bold>A</bold>) Plasmids encoding Myh9, Styxl2, or Mst1 (negative control) were co-expressed in C2C12 cells together with various siRNAs as indicated. Soluble whole cell extracts were subjected to Western blot analysis. OE: overexpression. N.S.: non-specific. The protein level of Myh9 was quantified at the bottom panel. *p-value &lt;0.05. (<bold>B</bold>) HEK 293T cells were transfected with various constructs as indicated. Various inhibitors of the autophagy-lysosome pathway (50 μM LY294002, 100 μM Chloroquine, 100 nM BafA1, 20 mM NH<sub>4</sub>Cl) were added to the cell culture 6 hr before harvest. OE: overexpression. (<bold>C</bold>) HEK 293T cells were co-transfected with the plasmids as indicated. 18 hr later, 100 nM of BafA1 was added to the culture medium. After another 6 hr, the soluble whole cell lysates were subjected to immunoprecipitation (IP) with an anti-Myc antibody, and the immunoprecipitated proteins were further analysed by Western blot (WB). The red arrow indicates Flag-Styxl2. (<bold>D</bold>) The schematic shows that Styxl2 promotes sarcomere assembly by binding to and targeting non-muscle myosin IIs for degradation, which facilitates their eventual replacement by muscle myosin II during sarcomere maturation.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig7">Figure 7A</xref> (anti-Styxl2, anti-Myh9, and N.S.).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig7">Figure 7A</xref> (anti-Styxl2, anti-Myh9, and N.S.) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (anti-Myh9, anti-Styxl2ΔN509, anti-Mst1, and anti-Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata4"><label>Figure 7—source data 4.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (anti-Myh9, anti-Styxl2ΔN509, anti-Mst1, and anti-Tubulin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata5"><label>Figure 7—source data 5.</label><caption><title>Original scans for the Western blot analysis of input and IP in <xref ref-type="fig" rid="fig7">Figure 7C</xref> (anti-Flag and anti-HA).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata6"><label>Figure 7—source data 6.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig7">Figure 7C</xref> (anti-Flag and anti-HA) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Proteasome is not involved in Styxl2-mediated degradation of NM IIs.</title><p>C2C12 cells were transfected with a Styxl2-expressing plasmid. 12 hr later, MG132 (4 μM) or DMSO was added into the medium. After another 12 hr, the cells were harvested for Western blot analysis. OE: overexpression.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Original scans for the Western blot analysis in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> (anti-Myh9, anti-Myh10, anti-Styxl2, and Loading).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7s1sdata2"><label>Figure 7—figure supplement 1—source data 2.</label><caption><title>A PDF file showing original scans of the relevant Western blot analysis in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> (anti-Myh9, anti-Myh10, anti-Styxl2, and Loading) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-87434-fig7-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-fig7-figsupp1-v1.tif"/></fig></fig-group><p>It is known that some ubiquitinated proteins (such as sarcomeric titin) are degraded by selective autophagy (<xref ref-type="bibr" rid="bib9">Bogomolovas et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">Kirkin et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Pankiv et al., 2007</xref>; <xref ref-type="bibr" rid="bib78">Shaid et al., 2013</xref>; <xref ref-type="bibr" rid="bib97">Zaffagnini and Martens, 2016</xref>). A recent report showed that Myh9 could also undergo Nek9-mediated selective autophagy (<xref ref-type="bibr" rid="bib96">Yamamoto et al., 2021</xref>), suggesting that Myh9 is ubiquitinated. To find out whether Styxl2 promotes ubiquitination of NM IIs, we co-transfected HEK 293T cells with plasmids encoding Myh9 and ubiquitin together with a plasmid encoding either Mst1 or Styxl2. Compared to the Mst1 control, we found that Styxl2 indeed promoted the ubiquitination of Myh9 (<xref ref-type="fig" rid="fig7">Figure 7C</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Styxl2 is a pseudophosphatase that functions independently of its conserved phosphatase domain</title><p>Pseudophosphatases are present in multicellular organisms ranging from <italic>C. elegans</italic> to humans (<xref ref-type="bibr" rid="bib33">Hinton, 2019</xref>; <xref ref-type="bibr" rid="bib67">Reiterer et al., 2020</xref>). Moreover, pseudophosphatases have also been identified in plants (<xref ref-type="bibr" rid="bib6">Bellec et al., 2002</xref>). Recently, 26 pseudophosphatase domains, including the phosphatase domain of Styxl2, were bioinformatically identified in the human genome (<xref ref-type="bibr" rid="bib11">Chen et al., 2017</xref>). Due to the absence of one or several conserved amino acids including the catalytic cysteine, pseudophosphatases are not expected to possess the phosphatase activity. STYX, the first molecularly characterized pseudophosphatase, was identified in 1995 as a phosphoserine/threonine/tyrosine-binding protein (<xref ref-type="bibr" rid="bib92">Wishart et al., 1995</xref>). The substitution of the catalytic cysteine by glycine in the active site motif leads to the loss of its catalytic activity (<xref ref-type="bibr" rid="bib65">Reiterer et al., 2013</xref>; <xref ref-type="bibr" rid="bib92">Wishart et al., 1995</xref>). In addition to STYX, the functions of several other pseudophosphatases from <italic>C. elegans</italic> to humans have also been characterized (<xref ref-type="bibr" rid="bib13">Cheng et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Hinton et al., 2010</xref>; <xref ref-type="bibr" rid="bib50">Maruyama et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Nakhro et al., 2013</xref>; <xref ref-type="bibr" rid="bib83">Tomar et al., 2019</xref>). These reports unequivocally demonstrate that pseudophosphatases are not simply evolution relics but play essential roles in multicellular organisms.</p><p>Pseudophosphatases exert their functions via diverse modes including direct competition with other proteins by binding to a phospho-residue-containing motif, modulation of the phosphatase activity by binding to an active phosphatase, sequestration of target proteins in specific subcellular locations, and integration of signals by simultaneous binding with multiple proteins (<xref ref-type="bibr" rid="bib33">Hinton, 2019</xref>; <xref ref-type="bibr" rid="bib67">Reiterer et al., 2020</xref>). The original report on STYX showed that mutation of the glycine in the conserved H<underline>G</underline>X<sub>5</sub>R motif back to cysteine restored the phosphatase activity (<xref ref-type="bibr" rid="bib92">Wishart et al., 1995</xref>), suggesting that the three-dimensional structure of the phosphatase domain in STYX is still folded properly. Thus, some pseudophosphatases are thought to function by binding to specific phosphorylated substrates, which is the case for pseudophosphatases EGG-4/5 and Pas2 (<xref ref-type="bibr" rid="bib6">Bellec et al., 2002</xref>; <xref ref-type="bibr" rid="bib13">Cheng et al., 2009</xref>; <xref ref-type="bibr" rid="bib19">Da Costa et al., 2006</xref>). In these examples, pseudophosphatases bind the phosphorylated sites of selected target proteins through their inactive phosphatase domains and prevent them from binding other interacting proteins or active phosphatases. However, this is not the only way pseudophosphatases function. MTMR13, a pseudophosphatase, functions by binding to MTMR2, an active lipid phosphatase, to regulate its phosphatase activity. Mutations in either <italic>MTMR13</italic> or <italic>MTMR2</italic> are causally linked to human Type 4B Charcot-Marie-Tooth disease, an inherited disorder of the peripheral nervous system with abnormal nerve myelination (<xref ref-type="bibr" rid="bib7">Berger et al., 2006</xref>; <xref ref-type="bibr" rid="bib69">Robinson and Dixon, 2005</xref>).</p><p>Unlike several other characterized pseudophosphatases that function via their conserved phosphatase domains, Styxl2 appears to function independently of its phosphatase domain as the phosphatase domain of Styxl2 is dispensable for its ability to induce degradation of NM IIs and to rescue the sarcomere defects in the <italic>Styxl2</italic> morphant zebrafish (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>). Such a phosphatase domain-independent mode of action is also observed in His Domain Protein Tyrosine Phosphatase (HD-PTP or PTPN23), a pseudophosphatase known to facilitate endosomal cargo sorting and the degradation of multiple membrane receptors including epidermal growth factor receptor, platelet-derived growth factor receptor, MHC class I and Integrin α5β1 (<xref ref-type="bibr" rid="bib22">Doyotte et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Kharitidi et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Ma et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Parkinson et al., 2015</xref>). Interestingly, a truncated fragment of HD-PTP without its phosphatase domain is still capable of promoting endosomal trafficking of cargo proteins like epidermal growth factor (EGF) (<xref ref-type="bibr" rid="bib22">Doyotte et al., 2008</xref>).</p></sec><sec id="s3-2"><title>Styxl2 facilitates de novo sarcomere assembly by promoting autophagy-dependent degradation of non-muscle myosin IIs</title><p>Although absent in invertebrates, Styxl2 is expressed and conserved in vertebrates. The specific involvement of Styxl2 in sarcomere assembly is supported by its restricted expression in striated muscles. Interestingly, mutation in the coding region of <italic>STYXL2</italic> and abnormal CpG methylation at the <italic>STYXL2</italic> locus were detected in some patients with congenital heart defects (CHD), suggesting a possible link of <italic>STYXL2</italic> to CHD (<xref ref-type="bibr" rid="bib3">Arrington et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Radhakrishna et al., 2016</xref>). Moreover, its role in sarcomere assembly is also conserved in vertebrates as interference of the gene expression in zebrafish by either a transposon integration or morpholino oligos leads to severe defects in sarcomere assembly (<xref ref-type="bibr" rid="bib25">Fero et al., 2014</xref>; <xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). However, Styxl2 is not essential for sarcomere assembly as sarcomeres in <italic>Drosophila</italic> flight muscles can normally assemble in the absence of a Styxl2 homolog. Furthermore, we could still find residual sarcomeres in skeletal muscles of conditional <italic>Styxl2</italic> KO mice (driven by either <italic>Pax7<sup>Cre</sup></italic> or <italic>Myf5<sup>Cre</sup></italic>) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>).</p><p>Although the highly-ordered sarcomere structure has been known for many years, it remains controversial how sarcomeres correctly assemble. Several different but not mutually exclusive models have been proposed (<xref ref-type="bibr" rid="bib73">Rui et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Sanger et al., 2006</xref>; <xref ref-type="bibr" rid="bib76">Sanger et al., 2017</xref>). Studies in <italic>Drosophila</italic>, <italic>C. elegans</italic>, and mice underscore an essential role for integrin in initiating the assembly of sarcomeres (<xref ref-type="bibr" rid="bib73">Rui et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Sparrow and Schöck, 2009</xref>). For example, β1 integrin was shown to be essential for sarcomere assembly in mice (<xref ref-type="bibr" rid="bib77">Schwander et al., 2003</xref>). Among the existing sarcomere assembly models, the prevailing model of sarcomere assembly is called premyofibril model (<xref ref-type="bibr" rid="bib68">Rhee et al., 1994</xref>; <xref ref-type="bibr" rid="bib74">Sanger et al., 2006</xref>; <xref ref-type="bibr" rid="bib76">Sanger et al., 2017</xref>). In this model, α-actinin, skeletal muscle actin, and non-muscle myosin IIs (NM IIs) first assemble to form mini-sarcomeres or premyofibrils at the cell periphery. Then, additional sarcomeric proteins like titin, nebulin, troponin, and myomesin will be incorporated and NM IIs will be eventually replaced by skeletal muscle myosin in mature sarcomeres (<xref ref-type="bibr" rid="bib89">White et al., 2014</xref>; <xref ref-type="bibr" rid="bib90">White et al., 2018</xref>). Consistent with this model, germline knockout of NM IIB (i.e. Myh10) in mice led to early lethality between E14.5 and birth and sarcomere structural defects in embryonic cardiomyocytes (<xref ref-type="bibr" rid="bib85">Tullio et al., 1997</xref>). Similarly, defective sarcomeres were also observed in embryonic muscles of stage-17 mutant fly null for <italic>zipper</italic> (<italic>zip</italic>), the <italic>Drosophila</italic> gene encoding the heavy chain of NM II (<xref ref-type="bibr" rid="bib8">Bloor and Kiehart, 2001</xref>; <xref ref-type="bibr" rid="bib43">Loison et al., 2018</xref>). Moreover, a recent paper using human iPSC-derived cardiomyocytes demonstrated that nascent sarcomeres assemble directly from muscle actin stress fibers (<xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>). Both MYH9 and MYH10 are present in muscle actin stress fibers with MYH10 being essential for sarcomere assembly. Consistent with the premyofibril model, NM IIs are found to be replaced by muscle myosin IIs in mature sarcomeres (<xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>). Nevertheless, the view of the involvement of NM IIs in early sarcomere assembly is also challenged by several studies. Unlike germline knockout of NM IIB, cardiac-specific knockout of NM IIB in adult mice did not generate obvious defects in sarcomere structures (<xref ref-type="bibr" rid="bib46">Ma et al., 2009</xref>). Although NM IIA is not detected in embryonic hearts, loss of cardiac NM IIB led to increased expression of NM IIA, suggesting that NM IIA may compensate for the loss of NM IIB in NM IIB-null embryonic cardiomyocytes (<xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>; <xref ref-type="bibr" rid="bib85">Tullio et al., 1997</xref>). Moreover, it was also suspected that the cardiomyocyte-specific deletion of NM IIB occurs after the initial sarcomere assembly due to the expression timing of the Cre recombinase under the control of the cardiac α-MHC promoter (<xref ref-type="bibr" rid="bib24">Fenix et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Ma et al., 2009</xref>). Furthermore, a recent study using CRISPR/Cas9 to knock out <italic>MYH9</italic> and <italic>MYH10</italic> genes either individually or in combination in human iPSC-derived cardiomyocytes showed that neither gene is required for sarcomere assembly in their cell culture models (<xref ref-type="bibr" rid="bib14">Chopra et al., 2018</xref>). It is puzzling at present why the results on the involvement of NM IIs in de novo sarcomere assembly differ in the two studies by Fenix et al<italic>.</italic> and Chopra et al. even though both studies used human iPSC-derived cardiomyocytes to assay de novo sarcomere assembly in cell culture.</p><p>It also remains unclear how NM IIs are replaced by muscle myosin during de novo sarcomere assembly in vertebrates. Our current study showed that Styxl2 interacts with NM IIs and induces their degradation via the autophagy-lysosome pathway. Autophagy is known to regulate sarcomere integrity (<xref ref-type="bibr" rid="bib51">Masiero et al., 2009</xref>; <xref ref-type="bibr" rid="bib56">Nakai et al., 2007</xref>). In particular, selective autophagy is known to degrade multiple ubiquitinated sarcomeric proteins including titin and filamin (<xref ref-type="bibr" rid="bib2">Arndt et al., 2010</xref>; <xref ref-type="bibr" rid="bib9">Bogomolovas et al., 2021</xref>). p62/SQSTM1 and NBR1 have been shown to act as adaptors linking ubiquitinated substrates to Atg8/LC3 that is localized on the membrane of autophagosome (<xref ref-type="bibr" rid="bib40">Kirkin et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Pankiv et al., 2007</xref>). Interestingly, a recent study on ciliogenesis showed that MYH9 is also degraded by selective autophagy in an NEK9-mediated manner (<xref ref-type="bibr" rid="bib96">Yamamoto et al., 2021</xref>). Consistently, we found that Styxl2 promotes the ubiquitination of Myh9 (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). It remains to be established whether Nek9 is involved in Styxl2-mediated autophagic degradation of NM IIs and whether ubiquitination of NM IIs is dependent on Nek9-mediated phosphorylation during myofibrillogenesis.</p><p>Our data showed that Styxl2 plays an indispensable role during embryonic myogenesis as conditional deletion of <italic>Styxl2</italic> during mouse embryo development using either <italic>Pax7<sup>Cre</sup></italic> or <italic>Myf5<sup>Cre</sup></italic> resulted in severe disruption of sarcomere structures in skeletal muscles and perinatal lethality (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In contrast, inducible deletion of <italic>Styxl2</italic> in adult muscles only led to mild defects in sarcomere structures (<xref ref-type="fig" rid="fig3">Figure 3F–J</xref>). It is likely that additional unknown molecules can compensate for the loss of Styxl2 in adult regenerating muscles. Such distinct roles of Styxl2 during development are also supported by differential expression patterns of Styxl2 and NM IIs: both are abundantly expressed in new-born and juvenile mice. While the protein levels of Myh9 and Myh10 start to drop one week after birth and become undetectable by three weeks after birth, that of Styxl2 is relatively stable in the first month after birth but starts to drop sharply by two months after birth (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). This is also consistent with our findings that Styxl2 is not required for the maintenance of the sarcomeres in adult muscles (<xref ref-type="fig" rid="fig3">Figure 3A–D</xref>).</p><p>In summary, our current study shows that Styxl2 critically regulates de novo sarcomere assembly by binding to NM IIs, enhancing their ubiquitination, and promoting their autophagic degradation, which ultimately facilitates sarcomere maturation in vivo (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Styxl2</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">MGI:MGI:2685055</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>D. rerio</italic>)</td><td align="left" valign="bottom">zStyxl2 (dusp27)</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">ZFIN:ZDB-GENE-140513–1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Styxl2<sup>flox/flox</sup></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 1.</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">EIIA-Cre</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #:003724</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Pax7<sup>CreERT2/+</sup></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #:017763</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Myf5<sup>Cre/+</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib82">Tallquist et al., 2000</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Pax7<sup>Cre/+</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib37">Keller et al., 2004</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Tg (HSA-MerCreMer)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib52">McCarthy et al., 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>D. rerio</italic>)</td><td align="left" valign="bottom">ABSR wild type fish</td><td align="left" valign="bottom">Prof. Zilong Wen (HKUST)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C2C12</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1772</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">HEK 293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Flag-Styxl2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Flag-Styxl2ΔN509</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Flag-Styxl2N513</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Myosin-IIA-GFP</td><td align="left" valign="bottom">addgenen</td><td align="left" valign="bottom">#38297</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">HA-Myh9</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">HA-Myh9-head</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">HA-Myh9-tail</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">HA-Myh10-head</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">HA-Myh10-tail</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>E. coli</italic>)</td><td align="left" valign="bottom">pcDNA3.1 mycBioID</td><td align="left" valign="bottom">addgene</td><td align="left" valign="bottom">#35700</td><td align="left" valign="bottom">Re-cloned into pcDNA3.0.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>D. rerio</italic>)</td><td align="left" valign="bottom">zStyxl2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>D. rerio</italic>)</td><td align="left" valign="bottom">zStyxl2ΔN493</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 2.</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Jak1 (Rabbit Polyclonal)</td><td align="left" valign="bottom">Upstate</td><td align="left" valign="bottom">Cat#: 06–272</td><td align="left" valign="bottom">IB(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Stat1 (Rabbit Polyclonal)</td><td align="left" valign="bottom">Upstate</td><td align="left" valign="bottom">Cat#: 06–501</td><td align="left" valign="bottom">IB(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-β-Tubulin (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#: T4026</td><td align="left" valign="bottom">IB(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-sarcomere MHC (Mouse monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">MF20</td><td align="left" valign="bottom">IB(1:1000)<break/>IF(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GAPDH (Mouse Monoclonal)</td><td align="left" valign="bottom">Ambion</td><td align="left" valign="bottom">Cat#: AM4300</td><td align="left" valign="bottom">IB(1:10000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Myh9 (Rabbit Polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 3403</td><td align="left" valign="bottom">IB(1:2000)<break/>IF(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Myh10 (Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat#: sc-376942</td><td align="left" valign="bottom">IB(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Flag (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">F3165</td><td align="left" valign="bottom">IF(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-HA (Mouse monoclonal)</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">12CA5</td><td align="left" valign="bottom">IB(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Styxl2 (Rabbit Polyclonal)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See Materials and methods, Section 7.<break/>IB(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-MEF2A (Rabbit Polyclonal)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Immunize rabbits with mouse MEF2A.</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Flag (Rabbit Polyclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">F7425</td><td align="left" valign="bottom">IF(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-HA (Rabbit polyclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat#: sc-805</td><td align="left" valign="bottom">IF(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Myc (Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat#: sc-40</td><td align="left" valign="bottom">IB(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-α-Actinin (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#: A7732</td><td align="left" valign="bottom">IF(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Prox1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Angiobio</td><td align="left" valign="bottom">Cat#: 11–002 P</td><td align="left" valign="bottom">IF(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-slow myosin heavy chain (Mouse monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">F59</td><td align="left" valign="bottom">IF(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-myosin heavy chain (Mouse monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">A4.1025</td><td align="left" valign="bottom">IF(1:200)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pRetroX-Tet-On Advanced (plasmid)</td><td align="left" valign="bottom">Dr. Yusong Guo (HKUST)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Styxl2-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCCATCCACCTCTCCTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Styxl2-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTCCTGTCATCCATCTTCTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh9-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCCCTGCTAGATGAGGAGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh9-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CTTGGGCTTCTGGAACTTGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh10-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGAATCCTTTGGAAATGCGAAGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh10-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCCCAACAATATAGCCAGTTAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Gapdh-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CCCACTCTTCCACCTTCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Gapdh-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTTGGAGGCCATGTAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">siGFP (negative control)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">siRNA</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTGACCCTGAAGTTCATC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">siJak1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">siRNA</td><td align="left" valign="bottom"><named-content content-type="sequence">GCCTGAGAGTGGAGGTAAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">siStat1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">siRNA</td><td align="left" valign="bottom"><named-content content-type="sequence">GGATCAAGTCATGTGCATA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">siATG5</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">siRNA</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCTCCTGGATTATGTCAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ctrl (negative control)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">morpholino</td><td align="left" valign="bottom"><named-content content-type="sequence">AGCACACAAAGGCGAAGGTCAACAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Styxl2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">morpholino</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTGATCCTCCACAGACGACGCCAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh10</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">morpholino</td><td align="left" valign="bottom"><named-content content-type="sequence">CTTCACAAATGTGGTCTTACCTTGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Atg5</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">morpholino</td><td align="left" valign="bottom"><named-content content-type="sequence">CACATCCTTGTCATCTGCCATTATC</named-content></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cardiotoxin</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat#: 217503</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">National Institutes of Health</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>ABSR wild-type zebrafish were maintained following standard procedures and the zygotes were collected for microinjection experiments. <italic>Pax7</italic><sup>CreERT2/+</sup> mice (Stock No: 017763) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). <italic>Myf5</italic><sup>Cre/+</sup>, <italic>Pax7</italic><sup>Cre/+</sup>, and Tg (HSA-MerCreMer) mice were generous gifts from Drs. Michael Rudnicki (Ottawa Hospital Research Institute, ON, Canada), Mario Capecchi (University of Utah, UT, USA), and Karyn Esser (University of Florida, FL, USA), respectively. <italic>Styxl2</italic><sup>flox/flox</sup> mice were generated by the Model Animal Research Centre (Nanjing University, Nanjing, China). To delete <italic>Styxl2</italic> in adult mice, tamoxifen dissolved in corn oil (15 mg/ml) was injected into adult mice intraperitoneally at 5 μl per gram of body weight for five consecutive days followed by another five doses of tamoxifen injection every 3–4 days. All animals were maintained and handled following the protocols approved by the Animal Ethics Committee of the Hong Kong University of Science and Technology.</p></sec><sec id="s4-2"><title>Cell culture and DNA constructs</title><p>C2C12 cells and HEK 293T cells were purchased from ATCC (Manassas, VA, USA). To ensure the cell quality, low-passage cells were used and the cell morphology was regularly examined. For C2C12 cells, the differentiation potential was also regularly examined by the expression of selected differentiation markers. In addition, DAPI staining was employed to detect the mycoplasma contamination in cell culture. C2C12 cells were maintained in growth medium (GM) (Dulbecco’s modified Eagle’s medium supplemented with 20% fetal bovine serum, 100 Units/ml penicillin, and 100 μg/ml streptomycin) and differentiation was induced with differentiation medium (DM) (Dulbecco’s modified Eagle’s medium supplemented with 2% horse serum, 100 Units/ml penicillin, and 100 μg/ml streptomycin). HEK 293T cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 Units/ml penicillin, and 100 μg/ml streptomycin. Mouse Styxl2, Styxl2ΔN509, and Styxl2N513 were amplified from a mouse muscle cDNA library and inserted into a modified pcDNA3.0 vector containing a Flag-expressing cassette to generate constructs encoding Flag-Styxl2, Flag-Styxl2ΔN509, and Flag-Styxl2N513. BirA* was amplified from pcDNA3.1 mycBioID (addgene, #35700) and an HA tag was added to its C-terminus. The cDNA encoding BirA*-HA was fused in-frame with that encoding mouse Styxl2 and cloned into the pRetroX-Tight-Pur vector (kindly provided by Dr. Yusong Guo at HKUST) to get pTight-Styxl2-BirA*-HA. Mouse Myh9, Myh9-head, and Myh9-tail were amplified from a plasmid encoding Myosin-IIA-GFP (addgene, #38297) and inserted into a modified pcDNA3.0 vector containing an HA-expressing cassette to generate constructs encoding HA-Myh9, HA-Myh9-head, and HA-Myh9-tail. Mouse Myh10-head and Myh10-tail were amplified from a mouse C2C12 cell cDNA library and inserted into a modified pcDNA3.0 vector containing an HA-expressing cassette to generate constructs encoding HA-Myh10-head and HA-Myh10-tail. Fish Styxl2 and Styxl2ΔN493 were amplified from a zebrafish cDNA library and inserted into pCS2+ vector to generate pCS2+-zStyxl2 and pCS2+-zStyxl2ΔN493.</p></sec><sec id="s4-3"><title>RNA extraction and RT-qPCR</title><p>Total RNA was extracted from C2C12 cells using the TRIzol Reagent (Invitrogen) following the manufacturer’s instructions. The reverse transcription was performed using an oligo-dT primer and the ImRrom-II Reverse Transcription System (Promega). The ABI 7700 Sequence Detection System (PE Applied-Biosystems) was used for qPCR and the relative fold change of genes of interest was analysed based on the 2<sup>-△△Ct</sup> method (<xref ref-type="bibr" rid="bib42">Livak and Schmittgen, 2001</xref>). The qPCR primers used were listed below:</p><list list-type="simple"><list-item><p><italic>Styxl2</italic>-F: 5’- <named-content content-type="sequence">GCCCATCCACCTCTCCTC</named-content>-3’</p></list-item><list-item><p><italic>Styxl2</italic>-R: 5’-<named-content content-type="sequence">GCTCCTGTCATCCATCTTCTC</named-content>-3’</p></list-item><list-item><p><italic>Myh9</italic>-F: 5’-<named-content content-type="sequence">GGCCCTGCTAGATGAGGAGT</named-content>-3’</p></list-item><list-item><p><italic>Myh9</italic>-R: 5’-<named-content content-type="sequence">CTTGGGCTTCTGGAACTTGG</named-content>-3’</p></list-item><list-item><p><italic>Myh10</italic>-F: 5’-<named-content content-type="sequence">GGAATCCTTTGGAAATGCGAAGA</named-content>-3’</p></list-item><list-item><p><italic>Myh10</italic>-R: 5’-<named-content content-type="sequence">GCCCCAACAATATAGCCAGTTAC</named-content>-3’</p></list-item><list-item><p><italic>Gapdh</italic>-F: 5’-<named-content content-type="sequence">CCCACTCTTCCACCTTCG</named-content>-3’</p></list-item><list-item><p><italic>Gapdh</italic>-R: 5’-<named-content content-type="sequence">TCCTTGGAGGCCATGTAG</named-content>-3’</p></list-item></list></sec><sec id="s4-4"><title>siRNA transfection</title><p>The following siRNAs were used to knock down specific genes. They were transfected into C2C12 cells using the Lipofectamine RNAiMax reagent (Thermo Fisher Scientific) following the manufacturer’s instructions.</p><list list-type="simple"><list-item><p><italic>GFP</italic> (negative control): 5’-<named-content content-type="sequence">GCTGACCCTGAAGTTCATC</named-content>-3’</p></list-item><list-item><p><italic>Jak1</italic>: 5’-<named-content content-type="sequence">GCCTGAGAGTGGAGGTAAC</named-content>-3’</p></list-item><list-item><p><italic>Stat1</italic>: 5’-<named-content content-type="sequence">GGATCAAGTCATGTGCATA</named-content>-3’</p></list-item><list-item><p><italic>Atg5</italic>: 5’-<named-content content-type="sequence">GGCTCCTGGATTATGTCAT</named-content>-3’</p></list-item></list></sec><sec id="s4-5"><title>Microarray</title><p>Total mRNA were extracted from duplicated samples and subjected to microarray analysis using the Affymetrix GeneChip Mouse Genome 430 2.0 Array. The data were analysed by the GeneSpring software and deposited to GEO (Accession number: GSE262242).</p></sec><sec id="s4-6"><title>Plasmid transfection</title><p>The Lipofectamine Transfection Reagent (Thermo Fisher Scientific) and the PLUS Reagent (Thermo Fisher Scientific) were used to transfect plasmids into C2C12 myoblasts following the manufacturer’s instructions. Polyethylenimine (PEI, Polysciences) was used to transfect plasmids into HEK 293T cells.</p></sec><sec id="s4-7"><title>Western blot</title><p>For cultured cells, Western blot was performed according to the standard procedures. For mouse tissues, the samples were homogenized using a T-25 digital IKA ULTRA-TURRAX disperser in a cell lysis buffer (25 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol) with a cocktail of protease inhibitors (20 mM <italic>p</italic>-nitrophenylphosphate, 20 mM β-glycerolphosphate, 0.5 mM phenylmethylsulfonyl fluoride, 2 μg/ml aprotinin, 0.5 μg/ml leupeptin, 0.7 μg/ml pepstatin, 50 μM sodium vanadate). The soluble lysates were used for Western blot. The primary antibodies used include anti-Jak1 (Upstate, 06–272), anti-Stat1 (Upstate, 06–501), anti-β-Tubulin (Sigma, T4026), anti-sarcomere myosin heavy chain (MHC) (DSHB, MF20), anti-GAPDH (Ambion, AM4300), anti-Myh9 (Cell Signaling, 3403), anti-Myh10 (Santa Cruz, sc-376942), anti-Flag (Sigma, F3165), and anti-HA (Roche, 12CA5). The Styxl2 antiserum was generated in-house by injecting rabbits with recombinant proteins spanning aa 2–142 of Styxl2 fused in-frame with glutathione S-transferase. The antiserum was purified with protein-G beads. The streptavidin-HRP was purchased from GE Healthcare (#RPN1231).</p></sec><sec id="s4-8"><title>Immunostaining</title><p>C2C12 myoblasts were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature, and then washed with 0.1% PBST. Then samples were permeabilized with 0.5% PBST for 20 min. Zebrafishes were fixed with PFA for 2–4 hr at room temperature and washed with 0.1% PBST. Then the fishes were permeabilized with cold acetone for 8 min at –20 °C. The following procedures are the same for two types of samples. After permeabilization, the samples were washed with 0.1% PBST and blocked with 4% IgG-free BSA for 1 hr and then incubated with the primary antibody at 4 °C overnight. Then samples were washed with 0.1% PBST and incubated with the secondary antibody at room temperature for 1 hr. The DNA was stained with 100 ng/ml 4′,6‐diamidino‐2‐phenylindole (DAPI). For fish slow muscles, the nucleus was stained with an anti-Prox1 antibody. The primary antibodies used include anti-Flag (Sigma, F7425), anti-HA (Santa Cruz, sc-805), anti-α-Actinin (Sigma, A7732), anti-Prox1 (Angiobio, 11–002 P), anti-slow myosin heavy chain (DSHB, F59), anti-myosin heavy chain (DSHB, A4.1025), and anti-sarcomere myosin heavy chain (MHC) (DSHB, MF20).</p></sec><sec id="s4-9"><title>Microinjection of zebrafish zygotes</title><p>The zygotes of zebrafish were collected in the morning. 2 nl of morpholino-containing solution was injected into fish zygotes as reported before (<xref ref-type="bibr" rid="bib36">Jin et al., 2009</xref>). The concentration of morpholinos used for microinjection was 0.3~0.5 mM. A control morpholino targeting a non-related gene was used as negative control (Ctrl-MO). Morpholinos used were synthesized by Gene Tools (USA) and their sequences were listed below:</p><list list-type="simple"><list-item><p>Ctrl-MO: 5’-<named-content content-type="sequence">AGCACACAAAGGCGAAGGTCAACAT</named-content>-3’</p></list-item><list-item><p><italic>Styxl2</italic>-MO: 5’-<named-content content-type="sequence">GCTGATCCTCCACAGACGACGCCAT</named-content>-3’</p></list-item><list-item><p><italic>Myh10</italic>-MO: 5’-<named-content content-type="sequence">CTTCACAAATGTGGTCTTACCTTGA</named-content>-3’</p></list-item><list-item><p><italic>Atg5</italic>-MO:5’-<named-content content-type="sequence">CACATCCTTGTCATCTGCCATTATC</named-content>-3’</p></list-item></list><p>The DNA constructs of pCS2+-zStyxl2 (with several synonymous mutations near the start codon of zStyxl2 to make it MO-resistant) and pCS2+-zStyxl2ΔN493 were linearized and used as templates for in vitro transcription. The mRNA was synthesized using the mMESSAGE mMACHINE SP6 Kit (Ambion, AM1340) followed by purification with the MEGAclear Transcription Clean-Up Kit (Invitrogen, AM1908). The purified mRNA was dissolved in RNase-free water and diluted to 150 ng/μl immediately before microinjection.</p></sec><sec id="s4-10"><title>Transmission electron microscopy</title><p>The heart and skeletal muscles were processed following the published protocols (<xref ref-type="bibr" rid="bib28">Graham and Orenstein, 2007</xref>). Then the samples were examined by a Hitachi H7650 transmission electron microscope (Hitachi High-Technologies). The sarcomere length was measured from electron microscopic images with a magnification of 50,000 X. The length of 3–5 sarcomeres was measured for each mouse and a total of six mice were examined. The results were presented as mean ± SD. The unpaired Student’s t-test was performed and p&lt;0.05 was considered statistically significant.</p></sec><sec id="s4-11"><title>Measurement of muscle force generation in vitro</title><p>The gastrocnemius muscle of left hindlimb was carefully dissected from mice together with femur condyle and Achilles tendon. The twitch and tetanic force generated by the dissected gastrocnemius muscle and the muscle cross-sectional area (MCSA) were measured following published protocols (<xref ref-type="bibr" rid="bib29">Guo et al., 2016</xref>). The force generated was recorded by the Dynamic Muscle Control system (DMC v5.4; Aurora Scientific) and analysed by the Dynamic Muscle Analysis system (DMA v3.2; Aurora Scientific). Both twitch and tetanic force were then normalized to the MCSA.</p></sec><sec id="s4-12"><title>BioID and mass spectrometry</title><p>C2C12 myoblasts were infected by a retrovirus carrying pRetroX-Tet-On Advanced (kindly provided by Dr. Yusong Guo, the Hong Kong University of Science and Technology) and selected by 1 mg/ml G418 to get the Tet-on cells. Then the Tet-on cells were infected by a retrovirus carrying pTight-Styxl2-BirA*-HA and selected by 1.5 μg/ml puromycin to obtain stable Tet-Styxl2-BirA*-HA cells. Thus, the expression of Styxl2-BirA*-HA is controlled by the Tet-on system in these stable C2C12 myoblasts. These stable cells were seeded in GM and cultured for 24 hr before being induced to differentiate in DM for 48 hr. The medium was then replaced with DM containing 50 μM biotin (control) or 50 μM biotin plus 1 μg/ml doxycycline. After another 24 hr, the control and doxycycline-treated cells were processed for mass spectrometry analysis following the published protocols (<xref ref-type="bibr" rid="bib71">Roux et al., 2018</xref>). Briefly, the biotinylated proteins were enriched by Dynabeads MyOne Streptavidin C1 (Invitrogen, #65001). The proteins bound to the beads were reduced with 10 mM Tris(2-carboxyethyl)phosphine hydrochloride (Sigma, C4706) at 40 °C for 30 min and alkylated with 20 mM Iodoacetamide (Sigma, I1149) in the dark for 30 min to prevent re-formation of the disulfide bond. The samples were digested with Trypsin Gold (Promega, V5280) overnight at 37 °C on a Thermomixer at 700 rpm followed by centrifugation. The supernatant was transferred to a new tube, acidified to pH2-3 by trifluoroacetic acid (Thermo Fisher, 85183), and desalted with a Pierce C18 spin column (Thermo Fisher Scientific, 89873). The tryptic peptides were labelled with iTRAQ reagents (AB Sciex, 4390812) following the manufacturer’s instructions. Briefly, peptides from control cells were labelled with iTRAQ tag 114 and those from doxycycline-treated cells were labelled with tag 115. The labelled samples were mixed and fractionated by an UltiMate 3000 RSLCnano system (Thermo Fisher Scientific). A C18 Acclaim PepMap RSLC analytical column (75 μm×250 mm, 2 µm, 100 Å) with a C18 nano Viper trap-column (0.3 mm × 5 mm, Thermo Fisher Scientific) was used for peptide elution and separation at a flow rate of 300 nl/min. The mobile phase contained buffer A (0.1% formic acid, 2% acetonitrile) and B (0.1% formic acid, 98% acetonitrile). The gradient was set as follows: 0 min, 3% B; 10 min, 3% B; 12 min, 7% B; 62 min, 20% B; 64 min, 30% B; 65 min, 80% B; 73 min, 80% B; 73.1 min, 3% B; and 90 min, 3% B. MS data were then acquired using an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) in a positive mode, with the following settings: (1) MS1 scan: 400–1600 m/z; resolution: 120,000; automatic gain control (AGC): 400,000; and maximum injection time: 50 ms; (2) The collision energy was set at 35% and orbitrap was used for MS2 scan as well; (3) MS2 scan starts from 100 m/z; resolution: 30,000; AGC: 50,000; and maximum injection time: 250 ms; (4) Exclusion window was set for 40 s; (5) The intensity threshold was set at 25,000. Data analysis was carried out using Mascot Deamon version 2.5.0 (Matrix Science) with standard settings for each instrument type and the data were searched against the <italic>Mus musculus</italic> database downloaded from SwissProt. A peptide tolerance of 10 ppm and fragment ion tolerance of 20 ppm were used. Carbamidomethylation of cysteine was specified as fixed modification, while oxidation of methionine and acetylation of protein N termini were set as variable modifications. The false discovery rate was set at 0.01 for proteins and peptide spectrum match. The 115/114 iTRAQ ratio of one protein was calculated based on the peak intensity of reporter ions by the software, and defined as Enrichment score for proteins in doxycycline-treated cells over that in control cells. The <italic>p</italic> values for each protein generated by the software were used for gene ontology analysis.</p></sec><sec id="s4-13"><title>Gene ontology enrichment analysis</title><p>All the biotinylated proteins enriched (with Enrichment score &gt;1) in cells expressing Styxl2-BirA*-HA were imported and analysed at Geneontology (<ext-link ext-link-type="uri" xlink:href="http://geneontology.org/">http://geneontology.org/</ext-link>). The terms in the cellular component category were presented.</p></sec><sec id="s4-14"><title>Immunoprecipitation</title><p>C2C12 cells or HEK293T cells were lysed in the lysis buffer with a cocktail of protease inhibitors. The soluble whole-cell lysates were first immunoprecipitated with an antibody targeting Styxl2, MEF2A (negative control), or Flag (Roche, F3165). The proteins co-precipitated were analysed by Western blot. In the ubiquitination assays, HEK 293T cells were lysed in the RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) with a cocktail of protease inhibitors and the soluble whole cell lysates were immunoprecipitated with an anti-Myc antibody (Santa Cruz, sc-40). The immunoprecipitated proteins were then analysed by Western blot.</p></sec><sec id="s4-15"><title>Injury-induced muscle regeneration</title><p>Avertin was used to anaesthetize mice at 0.5 mg per gram of body weight by intraperitoneal injection. Then 120 μl (for females) or 150 μl (for males) of 10 μM Cardiotoxin was injected into muscles of each hind limb to induce acute injury. After &gt;30 days, the muscles were dissected and tested. To examine protein levels at different time points, each tibialis anterior muscle was injected with 30 μl of 1.2% BaCl<sub>2</sub> to induce acute damage. The regenerating muscles were collected for Western blot at different time points.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Supervision, Investigation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animals were maintained and handled following the protocols approved by the Animal Ethics Committee of the Hong Kong University of Science and Technology.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-87434-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated in this study are either included in the main figures and figure supplements or deposited to the Gene Expression Omnibus (accession number: GSE262242).Source data are also provided for the data presented in both main figures and figure supplements.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Profiling of transcriptional targets of Jak1 and Stat1 in proliferating and differentiating myoblasts</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262242">GSE262242</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The project was supported by research grants from the Hong Kong Research Grant Council (C6018-19G, AoE/M-604/16, T13-602/21 N, and T13-605/18 W), the State Key Laboratory of Molecular Neuroscience at HKUST, the Hong Kong Center for Neurodegenerative Diseases (HKCeND), and the Shenzhen Bay Laboratory (S201101002, Guangdong, China). We thank Drs. K Esser, M Rudnicki, and M Capecchi for providing mouse Cre lines used in this study. We also thank Dr. Y Guo for providing the BioID vector and Drs. Y Dai and S Zhao for their help with zebrafish work.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Sasin</surname><given-names>J</given-names></name><name><surname>Bottini</surname><given-names>N</given-names></name><name><surname>Friedberg</surname><given-names>I</given-names></name><name><surname>Friedberg</surname><given-names>I</given-names></name><name><surname>Osterman</surname><given-names>A</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Dixon</surname><given-names>J</given-names></name><name><surname>Mustelin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Protein tyrosine phosphatases in the human genome</article-title><source>Cell</source><volume>117</volume><fpage>699</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.05.018</pub-id><pub-id pub-id-type="pmid">15186772</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arndt</surname><given-names>V</given-names></name><name><surname>Dick</surname><given-names>N</given-names></name><name><surname>Tawo</surname><given-names>R</given-names></name><name><surname>Dreiseidler</surname><given-names>M</given-names></name><name><surname>Wenzel</surname><given-names>D</given-names></name><name><surname>Hesse</surname><given-names>M</given-names></name><name><surname>Fürst</surname><given-names>DO</given-names></name><name><surname>Saftig</surname><given-names>P</given-names></name><name><surname>Saint</surname><given-names>R</given-names></name><name><surname>Fleischmann</surname><given-names>BK</given-names></name><name><surname>Hoch</surname><given-names>M</given-names></name><name><surname>Höhfeld</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Chaperone-assisted selective autophagy is essential for muscle maintenance</article-title><source>Current Biology</source><volume>20</volume><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2009.11.022</pub-id><pub-id pub-id-type="pmid">20060297</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrington</surname><given-names>CB</given-names></name><name><surname>Bleyl</surname><given-names>SB</given-names></name><name><surname>Matsunami</surname><given-names>N</given-names></name><name><surname>Bonnell</surname><given-names>GD</given-names></name><name><surname>Otterud</surname><given-names>BEM</given-names></name><name><surname>Nielsen</surname><given-names>DC</given-names></name><name><surname>Stevens</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Leppert</surname><given-names>MF</given-names></name><name><surname>Bowles</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Exome analysis of a family with pleiotropic congenital heart disease</article-title><source>Circulation. Cardiovascular Genetics</source><volume>5</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.111.961797</pub-id><pub-id pub-id-type="pmid">22337856</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avellaneda</surname><given-names>J</given-names></name><name><surname>Rodier</surname><given-names>C</given-names></name><name><surname>Daian</surname><given-names>F</given-names></name><name><surname>Brouilly</surname><given-names>N</given-names></name><name><surname>Rival</surname><given-names>T</given-names></name><name><surname>Luis</surname><given-names>NM</given-names></name><name><surname>Schnorrer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Myofibril and mitochondria morphogenesis are coordinated by a mechanical feedback mechanism in muscle</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>2091</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22058-7</pub-id><pub-id pub-id-type="pmid">33828099</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzedine</surname><given-names>H</given-names></name><name><surname>Bolino</surname><given-names>A</given-names></name><name><surname>Taïeb</surname><given-names>T</given-names></name><name><surname>Birouk</surname><given-names>N</given-names></name><name><surname>Di Duca</surname><given-names>M</given-names></name><name><surname>Bouhouche</surname><given-names>A</given-names></name><name><surname>Benamou</surname><given-names>S</given-names></name><name><surname>Mrabet</surname><given-names>A</given-names></name><name><surname>Hammadouche</surname><given-names>T</given-names></name><name><surname>Chkili</surname><given-names>T</given-names></name><name><surname>Gouider</surname><given-names>R</given-names></name><name><surname>Ravazzolo</surname><given-names>R</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Laporte</surname><given-names>J</given-names></name><name><surname>LeGuern</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma</article-title><source>American Journal of Human Genetics</source><volume>72</volume><fpage>1141</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1086/375034</pub-id><pub-id pub-id-type="pmid">12687498</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellec</surname><given-names>Y</given-names></name><name><surname>Harrar</surname><given-names>Y</given-names></name><name><surname>Butaeye</surname><given-names>C</given-names></name><name><surname>Darnet</surname><given-names>S</given-names></name><name><surname>Bellini</surname><given-names>C</given-names></name><name><surname>Faure</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Pasticcino2 is a protein tyrosine phosphatase-like involved in cell proliferation and differentiation in Arabidopsis</article-title><source>The Plant Journal</source><volume>32</volume><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1046/j.1365-313x.2002.01456.x</pub-id><pub-id pub-id-type="pmid">12472687</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Berger</surname><given-names>I</given-names></name><name><surname>Schaffitzel</surname><given-names>C</given-names></name><name><surname>Tersar</surname><given-names>K</given-names></name><name><surname>Volkmer</surname><given-names>B</given-names></name><name><surname>Suter</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Multi-level regulation of myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-2</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>569</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi473</pub-id><pub-id pub-id-type="pmid">16399794</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloor</surname><given-names>JW</given-names></name><name><surname>Kiehart</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>zipper Nonmuscle myosin-II functions downstream of PS2 integrin in <italic>Drosophila</italic> myogenesis and is necessary for myofibril formation</article-title><source>Developmental Biology</source><volume>239</volume><fpage>215</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1006/dbio.2001.0452</pub-id><pub-id pub-id-type="pmid">11784030</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogomolovas</surname><given-names>J</given-names></name><name><surname>Fleming</surname><given-names>JR</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Manso</surname><given-names>B</given-names></name><name><surname>Simon</surname><given-names>B</given-names></name><name><surname>Gasch</surname><given-names>A</given-names></name><name><surname>Markovic</surname><given-names>M</given-names></name><name><surname>Brunner</surname><given-names>T</given-names></name><name><surname>Knöll</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Labeit</surname><given-names>S</given-names></name><name><surname>Scheffner</surname><given-names>M</given-names></name><name><surname>Peter</surname><given-names>C</given-names></name><name><surname>Mayans</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Titin kinase ubiquitination aligns autophagy receptors with mechanical signals in the sarcomere</article-title><source>EMBO Reports</source><volume>22</volume><elocation-id>e48018</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201948018</pub-id><pub-id pub-id-type="pmid">34402565</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bönnemann</surname><given-names>CG</given-names></name><name><surname>Laing</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Myopathies resulting from mutations in sarcomeric proteins</article-title><source>Current Opinion in Neurology</source><volume>17</volume><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1097/00019052-200410000-00003</pub-id><pub-id pub-id-type="pmid">15367857</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MJ</given-names></name><name><surname>Dixon</surname><given-names>JE</given-names></name><name><surname>Manning</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomics and evolution of protein phosphatases</article-title><source>Science Signaling</source><volume>10</volume><elocation-id>eaag1796</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aag1796</pub-id><pub-id pub-id-type="pmid">28400531</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>RH</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>TY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ubiquitin-mediated regulation of autophagy</article-title><source>Journal of Biomedical Science</source><volume>26</volume><elocation-id>80</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-019-0569-y</pub-id><pub-id pub-id-type="pmid">31630678</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>KCC</given-names></name><name><surname>Klancer</surname><given-names>R</given-names></name><name><surname>Singson</surname><given-names>A</given-names></name><name><surname>Seydoux</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of MBK-2/DYRK by CDK-1 and the pseudophosphatases EGG-4 and EGG-5 during the oocyte-to-embryo transition</article-title><source>Cell</source><volume>139</volume><fpage>560</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.08.047</pub-id><pub-id pub-id-type="pmid">19879842</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>A</given-names></name><name><surname>Kutys</surname><given-names>ML</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Polacheck</surname><given-names>WJ</given-names></name><name><surname>Sheng</surname><given-names>CC</given-names></name><name><surname>Luu</surname><given-names>RJ</given-names></name><name><surname>Eyckmans</surname><given-names>J</given-names></name><name><surname>Hinson</surname><given-names>JT</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Force generation via β-cardiac myosin, titin, and α-actinin drives cardiac sarcomere assembly from cell-matrix adhesions</article-title><source>Developmental Cell</source><volume>44</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.12.012</pub-id><pub-id pub-id-type="pmid">29316444</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>KA</given-names></name><name><surname>McElhinny</surname><given-names>AS</given-names></name><name><surname>Beckerle</surname><given-names>MC</given-names></name><name><surname>Gregorio</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Striated muscle cytoarchitecture: an intricate web of form and function</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>18</volume><fpage>637</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.18.012502.105840</pub-id><pub-id pub-id-type="pmid">12142273</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>SJ</given-names></name><name><surname>Kruzynska-Frejtag</surname><given-names>A</given-names></name><name><surname>Kneer</surname><given-names>PL</given-names></name><name><surname>Machnicki</surname><given-names>M</given-names></name><name><surname>Koushik</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>What cardiovascular defect does my prenatal mouse mutant have, and why?</article-title><source>Genesis</source><volume>35</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/gene.10152</pub-id><pub-id pub-id-type="pmid">12481294</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>LM</given-names></name><name><surname>Waddell</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A tale of two DUSP27s: proposed resolution for the naming of distinct dual-specificity phosphatases</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>319</volume><fpage>C148</fpage><lpage>C150</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00201.2020</pub-id><pub-id pub-id-type="pmid">32491926</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>RW</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><chapter-title>Chapter 7 molecular structure of the sarcomere</chapter-title><person-group person-group-type="editor"><name><surname>Engel</surname><given-names>AC</given-names></name><name><surname>Franzini-Armstrong</surname><given-names>C</given-names></name></person-group><source>Myology</source><publisher-name>McGraw-Hill</publisher-name><fpage>129</fpage><lpage>166</lpage></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Da Costa</surname><given-names>M</given-names></name><name><surname>Bach</surname><given-names>L</given-names></name><name><surname>Landrieu</surname><given-names>I</given-names></name><name><surname>Bellec</surname><given-names>Y</given-names></name><name><surname>Catrice</surname><given-names>O</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>De Veylder</surname><given-names>L</given-names></name><name><surname>Lippens</surname><given-names>G</given-names></name><name><surname>Inzé</surname><given-names>D</given-names></name><name><surname>Faure</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Arabidopsis PASTICCINO2 is an antiphosphatase involved in regulation of cyclin-dependent kinase A</article-title><source>The Plant Cell</source><volume>18</volume><fpage>1426</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1105/tpc.105.040485</pub-id><pub-id pub-id-type="pmid">16698944</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>AT</given-names></name><name><surname>Tenenbaum</surname><given-names>L</given-names></name><name><surname>Berkhout</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tet-on systems for doxycycline-inducible gene expression</article-title><source>Current Gene Therapy</source><volume>16</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.2174/1566523216666160524144041</pub-id><pub-id pub-id-type="pmid">27216914</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dlugosz</surname><given-names>AA</given-names></name><name><surname>Antin</surname><given-names>PB</given-names></name><name><surname>Nachmias</surname><given-names>VT</given-names></name><name><surname>Holtzer</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>The relationship between stress fiber-like structures and nascent myofibrils in cultured cardiac myocytes</article-title><source>Journal of Cell Biology</source><volume>99</volume><fpage>2268</fpage><lpage>2278</lpage><pub-id pub-id-type="doi">10.1083/jcb.99.6.2268</pub-id><pub-id pub-id-type="pmid">6438115</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyotte</surname><given-names>A</given-names></name><name><surname>Mironov</surname><given-names>A</given-names></name><name><surname>McKenzie</surname><given-names>E</given-names></name><name><surname>Woodman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The Bro1-related protein HD-PTP/PTPN23 is required for endosomal cargo sorting and multivesicular body morphogenesis</article-title><source>PNAS</source><volume>105</volume><fpage>6308</fpage><lpage>6313</lpage><pub-id pub-id-type="doi">10.1073/pnas.0707601105</pub-id><pub-id pub-id-type="pmid">18434552</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumont</surname><given-names>NA</given-names></name><name><surname>Bentzinger</surname><given-names>CF</given-names></name><name><surname>Sincennes</surname><given-names>MC</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Satellite cells and skeletal muscle regeneration</article-title><source>Comprehensive Physiology</source><volume>5</volume><fpage>1027</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1002/cphy.c140068</pub-id><pub-id pub-id-type="pmid">26140708</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenix</surname><given-names>AM</given-names></name><name><surname>Neininger</surname><given-names>AC</given-names></name><name><surname>Taneja</surname><given-names>N</given-names></name><name><surname>Hyde</surname><given-names>K</given-names></name><name><surname>Visetsouk</surname><given-names>MR</given-names></name><name><surname>Garde</surname><given-names>RJ</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Nixon</surname><given-names>BR</given-names></name><name><surname>Manalo</surname><given-names>AE</given-names></name><name><surname>Becker</surname><given-names>JR</given-names></name><name><surname>Crawley</surname><given-names>SW</given-names></name><name><surname>Bader</surname><given-names>DM</given-names></name><name><surname>Tyska</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Gutzman</surname><given-names>JH</given-names></name><name><surname>Burnette</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Muscle-specific stress fibers give rise to sarcomeres in cardiomyocytes</article-title><source>eLife</source><volume>7</volume><elocation-id>e42144</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.42144</pub-id><pub-id pub-id-type="pmid">30540249</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fero</surname><given-names>K</given-names></name><name><surname>Bergeron</surname><given-names>SA</given-names></name><name><surname>Horstick</surname><given-names>EJ</given-names></name><name><surname>Codore</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>GH</given-names></name><name><surname>Ono</surname><given-names>F</given-names></name><name><surname>Dowling</surname><given-names>JJ</given-names></name><name><surname>Burgess</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Impaired embryonic motility in dusp27 mutants reveals a developmental defect in myofibril structure</article-title><source>Disease Models &amp; Mechanisms</source><volume>7</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1242/dmm.013235</pub-id><pub-id pub-id-type="pmid">24203884</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firestein</surname><given-names>R</given-names></name><name><surname>Nagy</surname><given-names>PL</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><name><surname>Huie</surname><given-names>P</given-names></name><name><surname>Conti</surname><given-names>M</given-names></name><name><surname>Cleary</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Sbf1</article-title><source>The Journal of Clinical Investigation</source><volume>109</volume><fpage>1165</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1172/JCI12589</pub-id><pub-id pub-id-type="pmid">11994405</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedberg</surname><given-names>I</given-names></name><name><surname>Nika</surname><given-names>K</given-names></name><name><surname>Tautz</surname><given-names>L</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Cerignoli</surname><given-names>F</given-names></name><name><surname>Friedberg</surname><given-names>I</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Mustelin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Identification and characterization of DUSP27, a novel dual-specific protein phosphatase</article-title><source>FEBS Letters</source><volume>581</volume><fpage>2527</fpage><lpage>2533</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2007.04.059</pub-id><pub-id pub-id-type="pmid">17498703</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>L</given-names></name><name><surname>Orenstein</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Processing tissue and cells for transmission electron microscopy in diagnostic pathology and research</article-title><source>Nature Protocols</source><volume>2</volume><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.304</pub-id><pub-id pub-id-type="pmid">17947985</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>A</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Chow</surname><given-names>SK</given-names></name><name><surname>Cheung</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Effect of low-magnitude, high-frequency vibration treatment on retardation of sarcopenia: senescence-accelerated mouse-p8 model</article-title><source>Rejuvenation Research</source><volume>19</volume><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1089/rej.2015.1759</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutzman</surname><given-names>JH</given-names></name><name><surname>Sahu</surname><given-names>SU</given-names></name><name><surname>Kwas</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Non-muscle myosin IIA and IIB differentially regulate cell shape changes during zebrafish brain morphogenesis</article-title><source>Developmental Biology</source><volume>397</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2014.10.017</pub-id><pub-id pub-id-type="pmid">25446029</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasty</surname><given-names>P</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Edmondson</surname><given-names>DG</given-names></name><name><surname>Venuti</surname><given-names>JM</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name><name><surname>Klein</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene</article-title><source>Nature</source><volume>364</volume><fpage>501</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/364501a0</pub-id><pub-id pub-id-type="pmid">8393145</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinton</surname><given-names>SD</given-names></name><name><surname>Myers</surname><given-names>MP</given-names></name><name><surname>Roggero</surname><given-names>VR</given-names></name><name><surname>Allison</surname><given-names>LA</given-names></name><name><surname>Tonks</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The pseudophosphatase MK-STYX interacts with G3BP and decreases stress granule formation</article-title><source>The Biochemical Journal</source><volume>427</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1042/BJ20091383</pub-id><pub-id pub-id-type="pmid">20180778</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinton</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of pseudophosphatases as signaling regulators</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1866</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2018.07.021</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinton</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pseudophosphatase MK-STYX: the atypical member of the MAP kinase phosphatases</article-title><source>The FEBS Journal</source><volume>287</volume><fpage>4221</fpage><lpage>4231</lpage><pub-id pub-id-type="doi">10.1111/febs.15426</pub-id><pub-id pub-id-type="pmid">32472731</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtzer</surname><given-names>H</given-names></name><name><surname>Hijikata</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>ZX</given-names></name><name><surname>Zhang</surname><given-names>ZQ</given-names></name><name><surname>Holtzer</surname><given-names>S</given-names></name><name><surname>Protasi</surname><given-names>F</given-names></name><name><surname>Franzini-Armstrong</surname><given-names>C</given-names></name><name><surname>Sweeney</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Independent assembly of 1.6 microns long bipolar MHC filaments and I-Z-I bodies</article-title><source>Cell Structure and Function</source><volume>22</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1247/csf.22.83</pub-id><pub-id pub-id-type="pmid">9113394</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Sood</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhen</surname><given-names>F</given-names></name><name><surname>English</surname><given-names>MA</given-names></name><name><surname>Liu</surname><given-names>PP</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Definitive hematopoietic stem/progenitor cells manifest distinct differentiation output in the zebrafish VDA and PBI</article-title><source>Development</source><volume>136</volume><fpage>647</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1242/dev.029637</pub-id><pub-id pub-id-type="pmid">19168679</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>MS</given-names></name><name><surname>Coffin</surname><given-names>CM</given-names></name><name><surname>Capecchi</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin</article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>2608</fpage><lpage>2613</lpage><pub-id pub-id-type="doi">10.1101/gad.1243904</pub-id><pub-id pub-id-type="pmid">15520281</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharitidi</surname><given-names>D</given-names></name><name><surname>Manteghi</surname><given-names>S</given-names></name><name><surname>Pause</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pseudophosphatases: methods of analysis and physiological functions</article-title><source>Methods</source><volume>65</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2013.09.009</pub-id><pub-id pub-id-type="pmid">24064037</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharitidi</surname><given-names>D</given-names></name><name><surname>Apaja</surname><given-names>PM</given-names></name><name><surname>Manteghi</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Malitskaya</surname><given-names>E</given-names></name><name><surname>Roldan</surname><given-names>A</given-names></name><name><surname>Gingras</surname><given-names>MC</given-names></name><name><surname>Takagi</surname><given-names>J</given-names></name><name><surname>Lukacs</surname><given-names>GL</given-names></name><name><surname>Pause</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interplay of endosomal ph and ligand occupancy in integrin α5β1 ubiquitination</article-title><source>Endocytic Sorting, and Cell Migration. Cell Reports</source><volume>13</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.024</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkin</surname><given-names>V</given-names></name><name><surname>McEwan</surname><given-names>DG</given-names></name><name><surname>Novak</surname><given-names>I</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A role for ubiquitin in selective autophagy</article-title><source>Molecular Cell</source><volume>34</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.04.026</pub-id><pub-id pub-id-type="pmid">19450525</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakso</surname><given-names>M</given-names></name><name><surname>Pichel</surname><given-names>JG</given-names></name><name><surname>Gorman</surname><given-names>JR</given-names></name><name><surname>Sauer</surname><given-names>B</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Efficient in vivo manipulation of mouse genomic sequences at the zygote stage</article-title><source>PNAS</source><volume>93</volume><fpage>5860</fpage><lpage>5865</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.12.5860</pub-id><pub-id pub-id-type="pmid">8650183</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loison</surname><given-names>O</given-names></name><name><surname>Weitkunat</surname><given-names>M</given-names></name><name><surname>Kaya-Çopur</surname><given-names>A</given-names></name><name><surname>Nascimento Alves</surname><given-names>C</given-names></name><name><surname>Matzat</surname><given-names>T</given-names></name><name><surname>Spletter</surname><given-names>ML</given-names></name><name><surname>Luschnig</surname><given-names>S</given-names></name><name><surname>Brasselet</surname><given-names>S</given-names></name><name><surname>Lenne</surname><given-names>PF</given-names></name><name><surname>Schnorrer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Polarization-resolved microscopy reveals a muscle myosin motor-independent mechanism of molecular actin ordering during sarcomere maturation</article-title><source>PLOS Biology</source><volume>16</volume><elocation-id>e2004718</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2004718</pub-id><pub-id pub-id-type="pmid">29702642</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>MH</given-names></name><name><surname>DiLullo</surname><given-names>C</given-names></name><name><surname>Schultheiss</surname><given-names>T</given-names></name><name><surname>Holtzer</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>JM</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Fischman</surname><given-names>DA</given-names></name><name><surname>Holtzer</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The vinculin/sarcomeric-alpha-actinin/alpha-actin nexus in cultured cardiac myocytes</article-title><source>The Journal of Cell Biology</source><volume>117</volume><fpage>1007</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1083/jcb.117.5.1007</pub-id><pub-id pub-id-type="pmid">1577864</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luis</surname><given-names>NM</given-names></name><name><surname>Schnorrer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanobiology of muscle and myofibril morphogenesis</article-title><source>Cells &amp; Development</source><volume>168</volume><elocation-id>203760</elocation-id><pub-id pub-id-type="doi">10.1016/j.cdev.2021.203760</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>ZX</given-names></name><name><surname>Zerfas</surname><given-names>P</given-names></name><name><surname>Blount</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Towbin</surname><given-names>JA</given-names></name><name><surname>Schneider</surname><given-names>MD</given-names></name><name><surname>Adelstein</surname><given-names>RS</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Conditional ablation of nonmuscle myosin II-B delineates heart defects in adult mice</article-title><source>Circulation Research</source><volume>105</volume><fpage>1102</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.200303</pub-id><pub-id pub-id-type="pmid">19815823</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Wardega</surname><given-names>P</given-names></name><name><surname>Mazaud</surname><given-names>D</given-names></name><name><surname>Klosowska-Wardega</surname><given-names>A</given-names></name><name><surname>Jurek</surname><given-names>A</given-names></name><name><surname>Engström</surname><given-names>U</given-names></name><name><surname>Lennartsson</surname><given-names>J</given-names></name><name><surname>Heldin</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Histidine-domain-containing protein tyrosine phosphatase regulates platelet-derived growth factor receptor intracellular sorting and degradation</article-title><source>Cellular Signalling</source><volume>27</volume><fpage>2209</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2015.07.020</pub-id><pub-id pub-id-type="pmid">26232618</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Acharya</surname><given-names>A</given-names></name><name><surname>Rodríguez-delaRosa</surname><given-names>A</given-names></name><name><surname>Marchiano</surname><given-names>F</given-names></name><name><surname>Dehapiot</surname><given-names>B</given-names></name><name><surname>Al Tanoury</surname><given-names>Z</given-names></name><name><surname>Rao</surname><given-names>J</given-names></name><name><surname>Díaz-Cuadros</surname><given-names>M</given-names></name><name><surname>Mansur</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>E</given-names></name><name><surname>Chardes</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Lenne</surname><given-names>PF</given-names></name><name><surname>Habermann</surname><given-names>BH</given-names></name><name><surname>Theodoly</surname><given-names>O</given-names></name><name><surname>Pourquié</surname><given-names>O</given-names></name><name><surname>Schnorrer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tension-driven multi-scale self-organisation in human iPSC-derived muscle fibers</article-title><source>eLife</source><volume>11</volume><elocation-id>e76649</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.76649</pub-id><pub-id pub-id-type="pmid">35920628</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>TG</given-names></name><name><surname>Kirk</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Under construction: The dynamic assembly, maintenance, and degradation of the cardiac sarcomere</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>148</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2020.08.018</pub-id><pub-id pub-id-type="pmid">32920010</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>R</given-names></name><name><surname>Velarde</surname><given-names>NV</given-names></name><name><surname>Klancer</surname><given-names>R</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Kadandale</surname><given-names>P</given-names></name><name><surname>Parry</surname><given-names>JM</given-names></name><name><surname>Hang</surname><given-names>JS</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Stewart-Michaelis</surname><given-names>A</given-names></name><name><surname>Schweinsberg</surname><given-names>P</given-names></name><name><surname>Grant</surname><given-names>BD</given-names></name><name><surname>Piano</surname><given-names>F</given-names></name><name><surname>Sugimoto</surname><given-names>A</given-names></name><name><surname>Singson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>EGG-3 regulates cell-surface and cortex rearrangements during EGG activation in <italic>Caenorhabditis elegans</italic></article-title><source>Current Biology</source><volume>17</volume><fpage>1555</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2007.08.011</pub-id><pub-id pub-id-type="pmid">17869112</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masiero</surname><given-names>E</given-names></name><name><surname>Agatea</surname><given-names>L</given-names></name><name><surname>Mammucari</surname><given-names>C</given-names></name><name><surname>Blaauw</surname><given-names>B</given-names></name><name><surname>Loro</surname><given-names>E</given-names></name><name><surname>Komatsu</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Reggiani</surname><given-names>C</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name><name><surname>Sandri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Autophagy is required to maintain muscle mass</article-title><source>Cell Metabolism</source><volume>10</volume><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2009.10.008</pub-id><pub-id pub-id-type="pmid">19945408</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>Srikuea</surname><given-names>R</given-names></name><name><surname>Kirby</surname><given-names>TJ</given-names></name><name><surname>Peterson</surname><given-names>CA</given-names></name><name><surname>Esser</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inducible Cre transgenic mouse strain for skeletal muscle-specific gene targeting</article-title><source>Skeletal Muscle</source><volume>2</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/2044-5040-2-8</pub-id><pub-id pub-id-type="pmid">22564549</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Yoshimori</surname><given-names>T</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Methods in mammalian autophagy research</article-title><source>Cell</source><volume>140</volume><fpage>313</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.028</pub-id><pub-id pub-id-type="pmid">20144757</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukund</surname><given-names>K</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Skeletal muscle: a review of molecular structure and function, in health and disease</article-title><source>Wiley Interdisciplinary Reviews. Systems Biology and Medicine</source><volume>12</volume><elocation-id>e1462</elocation-id><pub-id pub-id-type="doi">10.1002/wsbm.1462</pub-id><pub-id pub-id-type="pmid">31407867</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>MM</given-names></name><name><surname>Lawson</surname><given-names>JA</given-names></name><name><surname>Mathew</surname><given-names>SJ</given-names></name><name><surname>Hutcheson</surname><given-names>DA</given-names></name><name><surname>Kardon</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration</article-title><source>Development</source><volume>138</volume><fpage>3625</fpage><lpage>3637</lpage><pub-id pub-id-type="doi">10.1242/dev.064162</pub-id><pub-id pub-id-type="pmid">21828091</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>A</given-names></name><name><surname>Yamaguchi</surname><given-names>O</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Hikoso</surname><given-names>S</given-names></name><name><surname>Taniike</surname><given-names>M</given-names></name><name><surname>Omiya</surname><given-names>S</given-names></name><name><surname>Mizote</surname><given-names>I</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Asahi</surname><given-names>M</given-names></name><name><surname>Nishida</surname><given-names>K</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Otsu</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress</article-title><source>Nature Medicine</source><volume>13</volume><fpage>619</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1038/nm1574</pub-id><pub-id pub-id-type="pmid">17450150</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakhro</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>JM</given-names></name><name><surname>Hong</surname><given-names>YB</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Nam</surname><given-names>SH</given-names></name><name><surname>Yoon</surname><given-names>BR</given-names></name><name><surname>Yoo</surname><given-names>JH</given-names></name><name><surname>Koo</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>HL</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Choi</surname><given-names>KG</given-names></name><name><surname>Choi</surname><given-names>BO</given-names></name><name><surname>Chung</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>SET binding factor 1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3</article-title><source>Neurology</source><volume>81</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31829a3421</pub-id><pub-id pub-id-type="pmid">23749797</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>D</given-names></name><name><surname>Tahiliani</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Chandu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The ubiquitin-proteasome system</article-title><source>Journal of Biosciences</source><volume>31</volume><fpage>137</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1007/BF02705243</pub-id><pub-id pub-id-type="pmid">16595883</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newell-Litwa</surname><given-names>KA</given-names></name><name><surname>Horwitz</surname><given-names>R</given-names></name><name><surname>Lamers</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Non-muscle myosin II in disease: mechanisms and therapeutic opportunities</article-title><source>Disease Models &amp; Mechanisms</source><volume>8</volume><fpage>1495</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1242/dmm.022103</pub-id><pub-id pub-id-type="pmid">26542704</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankiv</surname><given-names>S</given-names></name><name><surname>Clausen</surname><given-names>TH</given-names></name><name><surname>Lamark</surname><given-names>T</given-names></name><name><surname>Brech</surname><given-names>A</given-names></name><name><surname>Bruun</surname><given-names>JA</given-names></name><name><surname>Outzen</surname><given-names>H</given-names></name><name><surname>Øvervatn</surname><given-names>A</given-names></name><name><surname>Bjørkøy</surname><given-names>G</given-names></name><name><surname>Johansen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>24131</fpage><lpage>24145</lpage><pub-id pub-id-type="doi">10.1074/jbc.M702824200</pub-id><pub-id pub-id-type="pmid">17580304</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>F</given-names></name><name><surname>Baboolal</surname><given-names>TG</given-names></name><name><surname>Peckham</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Actin mutations and their role in disease</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>3371</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21093371</pub-id><pub-id pub-id-type="pmid">32397632</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>F</given-names></name><name><surname>Peckham</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Disease mutations in striated muscle myosins</article-title><source>Biophysical Reviews</source><volume>12</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1007/s12551-020-00721-5</pub-id><pub-id pub-id-type="pmid">32651905</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkinson</surname><given-names>MDJ</given-names></name><name><surname>Piper</surname><given-names>SC</given-names></name><name><surname>Bright</surname><given-names>NA</given-names></name><name><surname>Evans</surname><given-names>JL</given-names></name><name><surname>Boname</surname><given-names>JM</given-names></name><name><surname>Bowers</surname><given-names>K</given-names></name><name><surname>Lehner</surname><given-names>PJ</given-names></name><name><surname>Luzio</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A non-canonical ESCRT pathway, including histidine domain phosphotyrosine phosphatase (HD-PTP), is used for down-regulation of virally ubiquitinated MHC class I</article-title><source>The Biochemical Journal</source><volume>471</volume><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1042/BJ20150336</pub-id><pub-id pub-id-type="pmid">26221024</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radhakrishna</surname><given-names>U</given-names></name><name><surname>Albayrak</surname><given-names>S</given-names></name><name><surname>Alpay-Savasan</surname><given-names>Z</given-names></name><name><surname>Zeb</surname><given-names>A</given-names></name><name><surname>Turkoglu</surname><given-names>O</given-names></name><name><surname>Sobolewski</surname><given-names>P</given-names></name><name><surname>Bahado-Singh</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genome-wide dna methylation analysis and epigenetic variations associated with congenital aortic valve stenosis (AVS)</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0154010</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0154010</pub-id><pub-id pub-id-type="pmid">27152866</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiterer</surname><given-names>V</given-names></name><name><surname>Fey</surname><given-names>D</given-names></name><name><surname>Kolch</surname><given-names>W</given-names></name><name><surname>Kholodenko</surname><given-names>BN</given-names></name><name><surname>Farhan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pseudophosphatase STYX modulates cell-fate decisions and cell migration by spatiotemporal regulation of ERK1/2</article-title><source>PNAS</source><volume>110</volume><fpage>E2934</fpage><lpage>E2943</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301985110</pub-id><pub-id pub-id-type="pmid">23847209</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiterer</surname><given-names>V</given-names></name><name><surname>Pawłowski</surname><given-names>K</given-names></name><name><surname>Farhan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>STYX: a versatile pseudophosphatase</article-title><source>Biochemical Society Transactions</source><volume>45</volume><fpage>449</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1042/BST20160279</pub-id><pub-id pub-id-type="pmid">28408485</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiterer</surname><given-names>V</given-names></name><name><surname>Pawłowski</surname><given-names>K</given-names></name><name><surname>Desrochers</surname><given-names>G</given-names></name><name><surname>Pause</surname><given-names>A</given-names></name><name><surname>Sharpe</surname><given-names>HJ</given-names></name><name><surname>Farhan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The dead phosphatases society: a review of the emerging roles of pseudophosphatases</article-title><source>The FEBS Journal</source><volume>287</volume><fpage>4198</fpage><lpage>4220</lpage><pub-id pub-id-type="doi">10.1111/febs.15431</pub-id><pub-id pub-id-type="pmid">32484316</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>D</given-names></name><name><surname>Sanger</surname><given-names>JM</given-names></name><name><surname>Sanger</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The premyofibril: evidence for its role in myofibrillogenesis</article-title><source>Cell Motility</source><volume>28</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/cm.970280102</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>FL</given-names></name><name><surname>Dixon</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot-Marie-Tooth disease</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>31699</fpage><lpage>31707</lpage><pub-id pub-id-type="doi">10.1074/jbc.M505159200</pub-id><pub-id pub-id-type="pmid">15998640</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>DI</given-names></name><name><surname>Raida</surname><given-names>M</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells</article-title><source>The Journal of Cell Biology</source><volume>196</volume><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1083/jcb.201112098</pub-id><pub-id pub-id-type="pmid">22412018</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>DI</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name><name><surname>May</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BioID: a screen for protein-protein interactions</article-title><source>Current Protocols in Protein Science</source><volume>91</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.1002/cpps.51</pub-id><pub-id pub-id-type="pmid">29516480</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudnicki</surname><given-names>MA</given-names></name><name><surname>Schnegelsberg</surname><given-names>PN</given-names></name><name><surname>Stead</surname><given-names>RH</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Arnold</surname><given-names>HH</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>MyoD or Myf-5 is required for the formation of skeletal muscle</article-title><source>Cell</source><volume>75</volume><fpage>1351</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90621-v</pub-id><pub-id pub-id-type="pmid">8269513</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rui</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sarcomere formation occurs by the assembly of multiple latent protein complexes</article-title><source>PLOS Genetics</source><volume>6</volume><elocation-id>e1001208</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1001208</pub-id><pub-id pub-id-type="pmid">21124995</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanger</surname><given-names>JW</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Siebrands</surname><given-names>CC</given-names></name><name><surname>Freeman</surname><given-names>N</given-names></name><name><surname>Du</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Stout</surname><given-names>AL</given-names></name><name><surname>Sanger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>How to build a myofibril</article-title><source>Journal of Muscle Research and Cell Motility</source><volume>26</volume><fpage>343</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1007/s10974-005-9016-7</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanger</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Holloway</surname><given-names>B</given-names></name><name><surname>Du</surname><given-names>A</given-names></name><name><surname>Sanger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Myofibrillogenesis in skeletal muscle cells in zebrafish</article-title><source>Cell Motility and the Cytoskeleton</source><volume>66</volume><fpage>556</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1002/cm.20365</pub-id><pub-id pub-id-type="pmid">19382198</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sanger</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Mi-Mi</surname><given-names>L</given-names></name><name><surname>Dube</surname><given-names>DK</given-names></name><name><surname>Sanger</surname><given-names>JM</given-names></name><name><surname>Pruyne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Assembly and maintenance of myofibrils in Striated muscle</chapter-title><person-group person-group-type="editor"><name><surname>Sanger</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><source>Handbook of Experimental Pharmacology</source><publisher-name>Elsevier</publisher-name><fpage>39</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/164_2016_53</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwander</surname><given-names>M</given-names></name><name><surname>Leu</surname><given-names>M</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Dorchies</surname><given-names>OM</given-names></name><name><surname>Ruegg</surname><given-names>UT</given-names></name><name><surname>Schittny</surname><given-names>J</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Beta1 integrins regulate myoblast fusion and sarcomere assembly</article-title><source>Developmental Cell</source><volume>4</volume><fpage>673</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/s1534-5807(03)00118-7</pub-id><pub-id pub-id-type="pmid">12737803</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaid</surname><given-names>S</given-names></name><name><surname>Brandts</surname><given-names>CH</given-names></name><name><surname>Serve</surname><given-names>H</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ubiquitination and selective autophagy</article-title><source>Cell Death and Differentiation</source><volume>20</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/cdd.2012.72</pub-id><pub-id pub-id-type="pmid">22722335</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparrow</surname><given-names>JC</given-names></name><name><surname>Schöck</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The initial steps of myofibril assembly: integrins pave the way</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>10</volume><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/nrm2634</pub-id><pub-id pub-id-type="pmid">19190670</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squire</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Molecular architecture in muscle contractile assemblies in advances in protein chemistry</article-title><source>Academic Press</source><volume>71</volume><fpage>17</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S0065-3233(04)71002-5</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Ip</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts</article-title><source>The Journal of Cell Biology</source><volume>179</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1083/jcb.200703184</pub-id><pub-id pub-id-type="pmid">17908914</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallquist</surname><given-names>MD</given-names></name><name><surname>Weismann</surname><given-names>KE</given-names></name><name><surname>Hellström</surname><given-names>M</given-names></name><name><surname>Soriano</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Early myotome specification regulates PDGFA expression and axial skeleton development</article-title><source>Development</source><volume>127</volume><fpage>5059</fpage><lpage>5070</lpage><pub-id pub-id-type="doi">10.1242/dev.127.23.5059</pub-id><pub-id pub-id-type="pmid">11060232</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomar</surname><given-names>VS</given-names></name><name><surname>Baral</surname><given-names>TK</given-names></name><name><surname>Nagavelu</surname><given-names>K</given-names></name><name><surname>Somasundaram</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Serine/threonine/tyrosine-interacting-like protein 1 (STYXL1), a pseudo phosphatase, promotes oncogenesis in glioma</article-title><source>Biochemical and Biophysical Research Communications</source><volume>515</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.05.093</pub-id><pub-id pub-id-type="pmid">31146910</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonks</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protein tyrosine phosphatases: from genes, to function, to disease</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>7</volume><fpage>833</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1038/nrm2039</pub-id><pub-id pub-id-type="pmid">17057753</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tullio</surname><given-names>AN</given-names></name><name><surname>Accili</surname><given-names>D</given-names></name><name><surname>Ferrans</surname><given-names>VJ</given-names></name><name><surname>Yu</surname><given-names>ZX</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name><name><surname>Preston</surname><given-names>YA</given-names></name><name><surname>Adelstein</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Nonmuscle myosin II-B is required for normal development of the mouse heart</article-title><source>PNAS</source><volume>94</volume><fpage>12407</fpage><lpage>12412</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.23.12407</pub-id><pub-id pub-id-type="pmid">9356462</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Sanger</surname><given-names>JM</given-names></name><name><surname>Sanger</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nonmuscle myosin II in cardiac and skeletal muscle cells</article-title><source>Cytoskeleton</source><volume>75</volume><fpage>339</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1002/cm.21454</pub-id><pub-id pub-id-type="pmid">29781105</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinfeld</surname><given-names>M</given-names></name><name><surname>Mani</surname><given-names>RS</given-names></name><name><surname>Abdou</surname><given-names>I</given-names></name><name><surname>Aceytuno</surname><given-names>RD</given-names></name><name><surname>Glover</surname><given-names>JNM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tidying up loose ends: the role of polynucleotide kinase/phosphatase in DNA strand break repair</article-title><source>Trends in Biochemical Sciences</source><volume>36</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2011.01.006</pub-id><pub-id pub-id-type="pmid">21353781</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitkunat</surname><given-names>M</given-names></name><name><surname>Kaya-Çopur</surname><given-names>A</given-names></name><name><surname>Grill</surname><given-names>SW</given-names></name><name><surname>Schnorrer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tension and force-resistant attachment are essential for myofibrillogenesis in <italic>Drosophila</italic> flight muscle</article-title><source>Current Biology</source><volume>24</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.02.032</pub-id><pub-id pub-id-type="pmid">24631244</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>J</given-names></name><name><surname>Barro</surname><given-names>MV</given-names></name><name><surname>Makarenkova</surname><given-names>HP</given-names></name><name><surname>Sanger</surname><given-names>JW</given-names></name><name><surname>Sanger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Localization of sarcomeric proteins during myofibril assembly in cultured mouse primary skeletal myotubes</article-title><source>Anatomical Record</source><volume>297</volume><fpage>1571</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1002/ar.22981</pub-id><pub-id pub-id-type="pmid">25125171</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Dube</surname><given-names>DK</given-names></name><name><surname>Sanger</surname><given-names>JW</given-names></name><name><surname>Sanger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Myofibril assembly in cultured mouse neonatal cardiomyocytes</article-title><source>The Anatomical Record</source><volume>301</volume><fpage>2067</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1002/ar.23961</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiese</surname><given-names>S</given-names></name><name><surname>Reidegeld</surname><given-names>KA</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Warscheid</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research</article-title><source>Proteomics</source><volume>7</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1002/pmic.200600422</pub-id><pub-id pub-id-type="pmid">17177251</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>MJ</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name><name><surname>Williams</surname><given-names>JA</given-names></name><name><surname>Dixon</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A single mutation converts: A novel phosphotyrosine binding domain into A dual-specificity phosphatase</article-title><source>The Journal of Biological Chemistry</source><volume>270</volume><fpage>26782</fpage><lpage>26785</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.45.26782</pub-id><pub-id pub-id-type="pmid">7592916</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>MJ</given-names></name><name><surname>Dixon</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The archetype STYX/dead-phosphatase complexes with a spermatid mRNA-binding protein and is essential for normal sperm production</article-title><source>PNAS</source><volume>99</volume><fpage>2112</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1073/pnas.251686198</pub-id><pub-id pub-id-type="pmid">11842224</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worby</surname><given-names>CA</given-names></name><name><surname>Gentry</surname><given-names>MS</given-names></name><name><surname>Dixon</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>30412</fpage><lpage>30418</lpage><pub-id pub-id-type="doi">10.1074/jbc.M606117200</pub-id><pub-id pub-id-type="pmid">16901901</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oncostatin M inhibits myoblast differentiation and regulates muscle regeneration</article-title><source>Cell Research</source><volume>21</volume><fpage>350</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/cr.2010.144</pub-id><pub-id pub-id-type="pmid">20956996</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Chino</surname><given-names>H</given-names></name><name><surname>Tsukamoto</surname><given-names>S</given-names></name><name><surname>Ode</surname><given-names>KL</given-names></name><name><surname>Ueda</surname><given-names>HR</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NEK9 regulates primary cilia formation by acting as a selective autophagy adaptor for MYH9/myosin IIA</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3292</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23599-7</pub-id><pub-id pub-id-type="pmid">34078910</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaffagnini</surname><given-names>G</given-names></name><name><surname>Martens</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanisms of selective autophagy</article-title><source>Journal of Molecular Biology</source><volume>428</volume><fpage>1714</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2016.02.004</pub-id><pub-id pub-id-type="pmid">26876603</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87434.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mizushima</surname><given-names>Noboru</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This paper presents an <bold>important</bold> finding: that Styxl2, a poorly characterized pseudo-phosphatase, plays a role in the sarcomere assembly by promoting the degradation of non-muscle myosins. The genetic evidence supporting the conclusions is <bold>compelling</bold>, although future work will be needed to elucidate the functional role and biochemical mechanism of autophagic degradation of non-muscle myosins. This work will be of interest to biologists studying muscle development, cell biology, and proteolysis.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87434.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This paper performed a functional analysis of the poorly characterized pseudo-phosphatase Styxl2, one of the targets of the Jak/Stat pathway in muscle cells. The authors propose that Styxl2 is essential for de novo sarcomere assembly by regulating autophagic degradation of non-muscle myosin IIs (NM IIs). Although a previous study by Fero et al. (2014) has already reported that Styxl2 is essential for the integrity of sarcomeres, this study provides new mechanistic insights into the phenomenon. In vivo studies in this manuscript are compelling; however, I feel the contribution of autophagy in the degradation of NM IIs is still unclear.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87434.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The authors investigated the role of the Jak1-Stat1 signaling pathway in myogenic differentiation by screening the transcriptional targets of Jak1-Stat1 and identified Styxl2, a pseudophosphatase, as one of them. Styxl2 expression was induced in differentiating muscles. The authors used a zebrafish knockdown model and conditional knockout mouse models to show that Styxl2 is required for de novo sarcomere assembly but is dispensable for the maintenance of existing sarcomeres. Styxl2 interacts with the non-muscle myosin IIs, Myh9 and Myh10, and promotes the replacement of these non-muscle myosin IIs by muscle myosin IIs through inducing autophagic degradation of Myh9 and Myh10. This function is independent of its phosphatase domain.</p><p>A previous study using zebrafish found that Styxl2 (previously known as DUSP27) is expressed during embryonic muscle development and is crucial for sarcomere assembly, but its mechanism remains unknown. This paper provides important information on how Styxl2 mediates the replacement of non-muscle myosin with muscle myosin during differentiation. This study may also explain why autophagy deficiency in muscles and the heart causes sarcomere assembly defects in previous mouse models.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87434.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Wu and colleagues are characterising the function of Styxl2 during muscle development, a pseudo-phosphatase that was already described to have some function in sarcomere morphogenesis or maintenance (Fero et al. 2014). The authors verify a role for Styxl2 in sarcomere assembly/maintenance using zebrafish embryonic muscles by morpholino knock-down and by a conditional Styxl2 allele in mice (knocked-out in satellite cells with Pax7 Cre).</p><p>Experiments using a tamoxifen inducible Cre suggest that Styxl2 is dispensable for sarcomere maintenance and only needed for sarcomere assembly.</p><p>BioID experiments with Styxl2 in C2C 12 myoblasts suggest binding of nonmuscle myosins (NMs) to Styxl2. Interestingly, both NMs are downregulated when muscles differentiate after birth or during regeneration in mice. This down-regulation is reduced in the Styxl2 mutant mice, demonstrating that Styxl2 is required for the degradation of these NMs.</p><p>Impressively, reducing one NM (zMyh10) by double morpholino injection in a Styxl2 morphant zebrafish, does improve zebrafish mobility and sarcomere structure. Degradation of Mhy9 is also stimulated in cell culture if Styxl2 is co-expressed. Surprisingly, the phosphatase domain is not needed for these degradation and sarcomere structure rescue effects. Inhibitor experiments suggest that Styxl2 does promote the degradation of NMs by promoting the selective autophagy pathway.</p><p>Strengths:</p><p>A major strength of the paper is the combination of various systems, mouse and fish muscles in vivo to test Styxl2 function, and cell culture including a C2C12 muscle cell line to assay protein binding or protein degradation as well as inhibitor studies that can suggest biochemical pathways.</p><p>A second strength is that this manuscript sheds new light on the still ill-characterised mechanism of sarcomere assembly in skeletal muscles.</p><p>Weakness:</p><p>The weaknesses of this manuscript have been largely eliminated during revision.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87434.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xianwei</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong University of Science and Technology</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yanfeng</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong University of Science and Technology</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Jin</given-names></name><role specific-use="author">Author</role><aff><institution>South China University of Technology</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Yong</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong Polytechnic University</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Qian</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong Polytechnic University</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Haidi</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong Polytechnic University</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yuying</given-names></name><role specific-use="author">Author</role><aff><institution>Chinese University of Hong Kong</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Chuan</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong University of Science and Technology</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Liwen</given-names></name><role specific-use="author">Author</role><aff><institution>the Chinese University of Hong Kong</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>Hong Kong</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Huating</given-names></name><role specific-use="author">Author</role><aff><institution>Chinese University of Hong Kong</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Zilong</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong University of Science and Technology</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>Hong Kong</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhongping</surname><given-names>Yao</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong Polytechnic University</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>Hong Kong</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Zhenguo</given-names></name><role specific-use="author">Author</role><aff><institution>Hong Kong University of Science and Technology</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>This paper performed a functional analysis of the poorly characterized pseudo-phosphatase Styxl2, one of the targets of the Jak/Stat pathway in muscle cells. The authors propose that Styxl2 is essential for de novo sarcomere assembly by regulating autophagic degradation of non-muscle myosin IIs (NM IIs). Although a previous study by Fero et al. (2014) has already reported that Styxl2 is essential for the integrity of sarcomeres, this study provides new mechanistic insights into the phenomenon. In vivo studies in this manuscript are compelling; however, I feel the contribution of autophagy in the degradation of NM IIs is still unclear.</p><p>Major concerns:</p><p>1. The contribution of autophagy in the degradation of Myh9 is still unclear to this reviewer.</p><p>It has been reported that autophagy is dispensable for sarcomere assembly in mice (Cell Metab, 2009, PMID; 1994508). In Fig. 7A, the authors showed that overexpressed Styxl2 downregulated the amount of ectopically expressed Myh9 in an ATG5-dependent manner in C2C12 cells; however, the experiment is far from a physiological condition. Therefore, the authors should test ATG5 knockdown and the genetic interaction between Styxl2 and ATG5 in vivo. That is, (1) loss of ATG5 on sarcomere assembly in zebrafish, and (2) the genetic interaction between Styxl2 and ATG5; co-injection of Styxl2 mRNA and ATG5-MO into the zebrafish embryos.</p></disp-quote><p>Our response: In fact, the reference cited by the reviewer (Cell Metab, 2009; PMID; 19945408) clearly indicated that autophagy is required for sarcomere assembly. Moreover, another paper using the fish extraocular muscle regeneration model (Autophagy, 2014, PMID: 27467399), also showed that the sarcomere structure was disrupted in the regenerated muscles when autophagy was inhibited by chloroquine. In addition, other references (Nature medicine, 2007, PMID: 17450150; Autophagy, 2010, PMID: 20431347) also showed that loss of Atg5 in mouse cardiac muscles led to disorganized sarcomere structure. We also performed the Atg5 knockdown experiments as suggested by the reviewer. However, the sarcomere structure defects were not so obvious as Styxl2 knockdown (see Author response image 1 below). In fact, it was reported that Atg5 knockdown may not be a desirable strategy to disrupt autophagy as it was found “--- only a small amount of Atg5 is needed for autophagy, knockdown of Atg5 to levels low enough to block autophagy might be difficult to achieve, --” (Nature medicine, 2007, PMID: 17450150). Due to the ineffectiveness of the Atg5 MO in our assays, we did not perform the second experiment suggested by the reviewer. Moreover, as Styxl2 is not a key component of the autophagy machinery, it is less likely that overexpression of Styxl2 alone can rescue the autophagy defects caused by Atg5.</p><fig id="sa4fig1" position="float"><label>Author response image 1.</label><caption><title>The fish zygotes were injected with Atg5 or Ctrl MO.</title><p>48 hpf, the fish were stained with an anti-Actinin antibody. Some fast muscle fibers were disrupted when Atg5 was knocked down. The number in numerator at the bottom of each image represents fish embryos showing normal Actinin staining pattern, while that in denominator represents the total number of embryos examined. Scale bar, 10 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-sa4-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>1. As referenced, Yamamoto et al. reported that Myh9 is degraded by autophagy. Mechanistically, Nek9 acts as an autophagic adaptor that bridges Atg8 and Myh9 through interactions with both. Inconsistent with the model, the authors mentioned on page 12, lines 365-367, &quot;A recent report showed that Myh9 could also undergo Nek9-mediated selective autophagy (Yamamoto et al., 2021), suggesting that Myh9 is ubiquitinated&quot;. I think it is not yet explored whether autophagic degradation of Myh9 requires its ubiquitination. Moreover, I cannot judge whether Myh9 is ubiquitinated in a Styxl2-dependent manner from the data in Fig. 7C. The author should test whether Nek9 is required for Myh9 degradation in muscles. If Nek plays a role in the Myh9 degradation, it would be better to remove Fig. 7C.</p></disp-quote><p>Our response: Indeed, as pointed out by the reviewer, it has not been explored whether Myh9 is ubiquitinated or not. However, it has been well-established that some proteins undergoing autophagic degradation are ubiquitinated, which are linked to Atg8/LC3 via p62 and NBR1 (Mol Cell, 2009, PMID: 19250911; J Biol Chem, 2007, PMID: 17580304). To improve the data quality, we repeated the Myh9 ubiquitination experiment in cells with or without Styxl2 by using a slightly different strategy: as shown in the revised Figure 7C, we first co-transfect HEK 293T cells with HA-Myh9, Myc-ubiquitin, and Flag-Styxl2. We then immunoprecipitated Myc-tagged Ubiquitin from the whole cell lysates, and then blot for HAMyh9. We detected an obvious increase in Ubiquitin-conjugated HA-Myh9 (revised Figure 7C). As suggested by the reviewer, we also tested whether knockdown of Nek9 affects the degradation of Myh9. We failed to detect an obvious effect (see Author response image 2 below) caused by Nek9 knockdown. One possible explanation for this negative result is that Nek9 itself is a negative regulator of selective autophagy (J Biol Chem, 2020, PMID: 31857374). By knocking it down, the functions of the autophagy machinery are expected to be enhanced instead of being impaired. This may explain why we failed to detect an effect on Myh9 degradation simply by knocking down Nek9. To further elucidate whether Nek9 is involved in Myh9 degradation in myoblasts, we may need to use a dominant-negative mutant of Nek9 missing the LCIII-binding motif as shown by Yamamoto (Nat Commun, 2021, PMID:34078910). This will be addressed in our future study.</p><fig id="sa4fig2" position="float"><label>Author response image 2.</label><caption><title>C2C12 cells were transfected with negative control siRNA (NC), siNek9#2 or siNek9#3.</title><p>18 h later, the cells were transfected with plasmids HA-Myh9 and Flag-Styxl2 or Flag-Stk24. After another 24 h, the cells were harvested for RT-qPCR (left panel) or western blot (right panel).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-sa4-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>1. In Fig. 5F, the protein level of Styxl2 and Myh10 should be checked because the efficiency of Myh10-MO was not shown anywhere in this manuscript.</p></disp-quote><p>Our response: As suggested by the reviewer, a Western blot showing the protein levels of Myh10 was shown in Figure 5-figure supplement 1B.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>The authors investigated the role of the Jak1-Stat1 signaling pathway in myogenic differentiation by screening the transcriptional targets of Jak1-Stat1 and identified Styxl2, a pseudophosphatase, as one of them. Styxl2 expression was induced in differentiating muscles. The authors used a zebrafish knockdown model and conditional knockout mouse models to show that Styxl2 is required for de novo sarcomere assembly but is dispensable for the maintenance of existing sarcomeres. Styxl2 interacts with the non-muscle myosin IIs, Myh9 and Myh10, and promotes the replacement of these non-muscle myosin IIs by muscle myosin IIs through inducing autophagic degradation of Myh9 and Myh10. This function is independent of its phosphatase domain.</p><p>A previous study using zebrafish found that Styxl2 (previously known as DUSP27) is expressed during embryonic muscle development and is crucial for sarcomere assembly, but its mechanism remains unknown. This paper provides important information on how Styxl2 mediates the replacement of non-muscle myosin with muscle myosin during differentiation. This study may also explain why autophagy deficiency in muscles and the heart causes sarcomere assembly defects in previous mouse models.</p><p><bold>Reviewer #3 (Public Review):</bold></p><p>Wu and colleagues are characterising the function of Styxl2 during muscle development, a pseudo-phosphatase that was already described to have some function in sarcomere morphogenesis or maintenance (Fero et al. 2014). The authors verify a role for Styxl2 in sarcomere assembly/maintenance using zebrafish embryonic muscles by morpholino knockdown and by a conditional Styxl2 allele in mice (knocked-out in satellite cells with Pax7 Cre).</p><p>Experiments using a tamoxifen inducible Cre suggest that Styxl2 is dispensable for sarcomere maintenance and only needed for sarcomere assembly.</p><p>BioID experiments with Styxl2 in C2C 12 myoblasts suggest binding of nonmuscle myosins (NMs) to Styxl2. Interestingly, both NMs are downregulated when muscles differentiate after birth or during regeneration in mice. This down-regulation is reduced in the Styxl2 mutant mice, suggesting that Styxl2 is required for the degradation of these NMs.</p><p>Impressively, reducing one NM (zMyh10) by double morpholino injection in a Styxl2 morphant zebrafish, does improve zebrafish mobility and sarcomere structure. Degradation of Mhy9 is also stimulated in cell culture if Styxl2 is co-expressed. Surprisingly, the phosphatase domain is not needed for these degradation and sarcomere structure rescue effects. Inhibitor experiments suggest that Styxl2 does promote the degradation of NMs by promoting the selective autophagy pathway.</p><p>Strengths:</p><p>A major strength of the paper is the combination of various systems, mouse and fish muscles in vivo to test Styxl2 function, and cell culture including a C2C12 muscle cell line to assay protein binding or protein degradation as well as inhibitor studies that can suggest biochemical pathways.</p><p>Weakness:</p><p>The weakness of this manuscript is that the sarcomere phenotypes and also the western blots are not quantified. Hence, we rely on judging the results from a single image or blot. Also, Styxl2 role in sarcomere biology was not entirely novel.</p><p>Few high resolution sarcomere images are shown, myosins have not been stained for.</p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Minor concerns:</p><p>1. The position of molecular weight markers should be shown in all Western blot data.</p></disp-quote><p>Our response: As suggested by the reviewer, the molecular weight markers have been added in the Western blot data.</p><disp-quote content-type="editor-comment"><p>1. Schematic models of Styxl2deltaN509 and N513 construct would be helpful for the readers.</p></disp-quote><p>Our response: A schematic has been added in Figure 6B (upper panel) to show Styxl2deltaN509 and Styxl2N513.</p><disp-quote content-type="editor-comment"><p>1. Several data were described but not shown (data not shown). I think the data need to be included in the main or supplemental figures.</p></disp-quote><p>Our response: As suggested by the reviewer, the raw data were now included in the Figure 6-figure supplement 1A and Figure 7-figure supplement 1.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>1. In Fig. 5E, the authors suggest that the needle touch response was improved by additional knockdown of Myh10. This is a bit confusing because the germline knockout of Myh10 is lethal (line 445). The authors should provide more explanation on this point. Additionally, it would be better to include Myh10-MO in Fig. 5E.</p></disp-quote><p>Our response:</p><p>In line 445 of our original manuscript, we stated that germline knockout of mouse Myh10 gene is lethal based on a published report (Proc Natl Acad Sci USA, 1997, PMID: 9356462). Here, in zebrafish zygotes, we only knocked down zMyh10, thus, we do not expect to get a lethal phenotype. In addition, other groups who knocked down Myh10 in fish also did not get a lethal phenotype (Dev Biol, 2015, PMID: 25446029). As to the control involving Myh10MO in the experiment in Fig.5E, we did include it in our experiments. As we did not observe any obvious effects on either motility or sarcomere structures, we did not include the data set in the figure.</p><p>1. It was suggested that Myh9 and Myh10 form a complex (Rao et al. PLoS One 9, e114087, 2014). Thus, the IP experiments do not rule out the possibility that Styxl2 directly interacts with either Myh9 or Myh10 and indirectly with the other.</p><p>Our response: In known myosin-II complexes, different myosin molecules can associate with each other through their tail domains (Bioarchitecture, 2013, PMID: 24002531). Thus, if we use fulllength myosin molecules in our co-immunoprecipitation assays, it will be difficult to exclude the possibility raised by the reviewer. However, by using truncated myosin proteins, we showed that the head domain of either Myh9 or Myh10 could interact with Styxl2 in the absence of the tail domain (Figure 4E, F). This result strongly suggests that both Myh9 and Myh10 can independently interact with Styxl2.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>1. The western blot shown in Figure 3B supporting the induced deletion of Styxl2 should be quantified. Ideally, some other blots, e.g., in Figure 5, too. Please add the age of the mice in Figure 5B to the figure legend.</p></disp-quote><p>Our response:</p><p>As suggested by the reviewer, we quantified the data in Figures.3B, 3F, 5B, 5D, and 7A and the data were included in the revised figures. In Fig.5B, we already indicated the age of the mice (i.e., P1) in the legend.</p><disp-quote content-type="editor-comment"><p>1. A quantification of the sarcomere phenotypes in the double knock-down of zMyh10 and Styxl2 compared to Styxl2 single would make the paper significantly stronger. Furthermore, a double morpholino control should be included to rule out any RNAi machinery 'dilution effect'.</p></disp-quote><p>Our response: As suggested by the reviewer, we quantified the sarcomere structures using the line scan analysis in ImageJ and the scan images were placed as inserts in the upper corner of the immunofluorescent images (revised Figures 5F, and 6C). To avoid potential “dilution effects”, in all the experiments involving the use of two different MOs, the total amount of MO was kept the same in all control samples by including a control MO (e.g., in samples treated with one specific MO, an equal amount of a control MO was also included, while in samples without any specific MO, twice as much control MO was used).</p><disp-quote content-type="editor-comment"><p>1. The sarcomere phenotypes in figure 6 should also be better quantified, for example using simple line scans of the alpha-actinin stains and assay periodicity or calculating the autocorrelation coefficients. How about myosin stains?</p></disp-quote><p>Our response: We quantified Figure 6C as suggested by the reviewer. We also performed myosin staining. The results were similar to that shown by the a-actinin antibody (see revised Figure 6-Fig supplement 1B).</p><disp-quote content-type="editor-comment"><p>1. Do the authors see periodic NMs patterns in developing mouse muscle fibers as indicated by the model in in in figure 7D? It is unclear if nonmuscle myosin is present in a PERIODIC pattern in early myofibrils. NM myosin periodic patterns that have been observed have a periodicity of only about 1 µm fitting the shorter length of the NM bipolar filaments (about 300 nm only, PMID 28114270).</p></disp-quote><p>Our response: The reviewer raised a good point here. Ideally, we should examine developing mouse muscle fibers to prove that NM shows periodic patterns. However, due to the difficulty in catching myocytes undergoing sarcomere assembly, the majority of the studies involving NM in sarcomeres use cultured cardiomyocytes. Using TA muscles from P1 new-born mice, we failed to detect the presence of NM in sarcomeres (see Author response image 3 below). Actually, nearly all the myofibers showed mature sarcomere pattern without the NM signal. More work is needed in the future to examine developing mouse fibers at different embryonic stages to look for the presence of NM in developing sarcomeres.</p><fig id="sa4fig3" position="float"><label>Author response image 3.</label><caption><title>The TA muscles were collected from male and female P1 mice.</title><p>The muscles were sectioned and co-stained for a-actinin (Actn) and Myh9. The majority of myofibrils is mature without the NM II signal. Scale bar, 10 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87434-sa4-fig3-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>1. Recent work suggested that mechanical tension is key to assemble the first long periodic myofibril containing immature sarcomeres. Tension is likely produced by a combination of NM and Mhc in the assembling sarcomeres themselves. This could be included in the introduction or discussion (PMIDs 24631244, 29316444, 29702642, 35920628).</p></disp-quote><p>Our response: We thank the reviewer for pointing to us additional relevant references. We have added them in the Introduction.</p><disp-quote content-type="editor-comment"><p>1. I suggest replacing &quot;sarcomeric muscles&quot; with &quot;striated muscles&quot;.</p></disp-quote><p>Our response: We revised the term in the manuscript as suggested by the reviewer.</p></body></sub-article></article>